Note: Descriptions are shown in the official language in which they were submitted.
WO 2021/050939
PCT/US2020/050490
METHODS AND SYSTEMS FOR THE RAPID DETECTION OF MICROORGANISMS
USING RECOMBINANT INFECTIOUS AGENTS TO EXPRESS AN INDICATOR
SUBUNIT
CROSS REFERENCE TO RELATED APPLICATION
[0001] The present application claims priority to U.S.
Provisional Application No.
62/898,945, filed on September 11, 2019. The disclosures of U.S. Application
Nos. 13/773,339,
14/625,481, 15;263,619, and 15/409,258 are incorporated by reference in their
entirety herein.
FIELD OF THE INVENTION
[0002] This disclosure relates to compositions, methods,
systems, and kits for the detection of
microorganisms using infectious agents_
BACKGROUND
[0003] There is a strong interest in improving speed and
sensitivity for detection of bacteria,
viruses, and other microorganisms in biological, food, water, and clinical
sample& Microbial
pathogens can cause substantial morbidity among humans and domestic animals,
as well as
immense economic loss. Also, detection of microorganisms is a high priority
for the Food and
Drug Administration (FDA) and Centers for Disease Control (CDC), as well as
the United States
Department of Agriculture (USDA), given outbreaks of life-threatening or fatal
illness caused by
ingestion of food contaminated with certain microorganisms, e.g., Escherichia
coil, Cronobacter
spp., Salmonella pp., Listeria spp., or Staphylococcus spp.
[0004] Traditional microbiological tests for the detection
of bacteria rely on non-selective and
selective enrichment cultures followed by plating on selective media and
further testing to
confirm suspect colonies. Such procedures can require several days. A variety
of rapid methods
have been investigated and introduced into practice to reduce the time
requirement. However,
these methods have drawbacks. For example, techniques involving direct
inununoassays or gene
probes generally require an overnight enrichment step in order to obtain
adequate sensitivity.
Polymerase chain reaction (PCR) tests also include an amplification step and
therefore are
capable of both very high sensitivity and selectivity; however, the sample
size that can be
1
CA 03150337 2022-3-7
WO 2021/050939
PCT/US2020/050490
economically subjected to PCR testing is limited. With dilute bacterial
suspensions, most small
subsarnples will be free of cells and therefore purification and/or lengthy
enrichment steps are
still required.
100051 The time required for traditional biological
enrichment is dictated by the growth rate
of the target bacterial population of the sample, by the effect of the sample
matrix, and by the
required sensitivity. In practice, most high sensitivity methods employ an
overnight incubation
and take about 24 hours overall. Due to the time required for cultivation,
these methods can take
up to three days, depending upon the organism to be identified and the source
of the sample.
This lag time is generally unsuitable as the contaminated food, water, or
other product may have
already made its way into livestock or humans. In addition, increases in
antibiotic-resistant
bacteria and biodefense considerations make rapid identification of bacterial
pathogens in water,
food and clinical samples critical priorities worldwide.
[0006] Therefore, there is a need for more rapid, simple,
and sensitive detection and
identification of microorganisms, such as bacteria and other potentially
pathogenic
microorganisms.
SUMMARY
100071 Embodiments of the disclosure comprise compositions, methods, systems,
and kits for
the detection of microorganisms such as. The disclosure may be embodied in a
variety of ways.
[0008] In some aspects, the disclosure comprises a recombinant indicator
bacteriophage
comprising an indicator gene inserted into the bacteriophage genome, wherein
the indicator gene
encodes a peptide subunit of an indicator protein (indicator protein product).
In certain
embodiments the indicator bacteriophage comprises a genetically modified
bacteriophage
genome derived from a bacteriophage that specifically recognizes a particular
bacteria of
interest.
[0009] In some embodiments of the recombinant indicator
bacteriophage, the peptide subunit
(labeling subunit) is part of a split reporter enzyme system, wherein the
reporter enzyme (i.e.,
indicator protein) is a luciferase. The luciferase can be naturally occurring,
such as Oplopizonts
2
CA 03150337 2022-3-7
WO 2021/050939
PCT/US2020/050490
luciferase, Firefly luciferase, Lucia luciferase, or Remitla luciferase, or it
can be a genetically
engineered luciferase such as NANOLUOV,
[0HO] Also disclosed herein are methods for preparing an indicator
bacteriophage. Some
embodiments include selecting a wild-type bacteriophage that specifically
infects a target
pathogenic bacterium; preparing a homologous recombination plasmid/vector
comprising an
indicator gene; transforming the homologous recombination plasmidIvector into
target
pathogenic bacteria; infecting the transformed target pathogenic bacteria with
the selected wild-
type bacteriophage, thereby allowing homologous recombination to occur between
the
plasmidivector and the bacteriophage genome; and isolating a particular clone
of recombinant
bacteriophage.
100111 In another aspect, the disclosure comprises a
method for detecting a particular bacteria
of interest in a sample comprising the steps of incubating the sample with a
recombinant
indicator bacteriophage comprising an indicator gene, wherein the indicator
gene encodes a first
subunit of an indicator protein, thereby producing an amount of progeny phage
and expressing
the first subunit; lysing the bacteria in the sample to release the amount of
progeny phage and the
first subunit; incubating the lysed sample in the presence of a detection
reagent, wherein the
detection reagent comprises a second subunit of an indicator protein, thereby
allowing the first
subunit and second subunit to reconstitute to form an indicator protein
complex; and detecting
the indicator protein complex, wherein positive detection of the indicator
protein complex
indicates that the particular bacteria of interest is present in the sample.
[0012] In some embodiments of methods for detecting bacteria, the sample is
first incubated
in conditions favoring growth for an enrichment period of 24 hours or less. 23
hours Of less, 22
hours or less, 21 hours or less, 20 hours or less, 19 hours or less, 18 hours
or less, 17 hours or
less, 16 hours or less, 15 hours or less, 14 hours or less, 13 hours or less,
12 hours or less, 11
hours or less, 10 hours or less, or 9 hours or less, 8 hours or less, 7 hours
or less, 6 hours or less,
5 hours or less, 4 hours or less, 3 hours or less, or 2 hours or less. In some
embodiments, the
sample is not enriched prior to detection. In some embodiments, the total time
to results is less
than 26 hours, 25 hours, 24 hours, 23 hours, 22 hours, 21 hours, 20 hours, 19
hours, 18 hours, 17
hours, 16 hours, 15 hours, 14 hours, 13 hours, 12 hours, 11 hours, 10 hours, 9
hours, 8 hours, 7
3
CA 03150337 2022-3-7
WO 2021/050939
PCT/US2020/050490
hours, 6 hours, 5 hours, 4 hours, 3 hours or 2 hours. In some embodiments, the
ratio of signal to
background generated by detecting the indicator is at least 2.0 or at least
2,5 or at least 3,0. In
some embodiments, the method detects as few as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10,
15, 20, 30, 40, 50,
60, 70, 80, 90, or 100 of the specific bacteria in a sample of a standard size
for the food safety
industry.
[0013] Additional embodiments include systems and kits for detecting
particular bacteria of
interest, wherein the systems or kits include an indicator bacteriophage
derived from
bacteriophage specific for the particular bacteria of interest. These systems
or kits can include
features described for the bacteriophage, compositions, and methods of the
disclosure. In still
other embodiments, the disclosure comprises non-transient computer readable
media for use with
methods or systems according to the disclosure.
BRIEF DESCRIPTION OF THE FIGURES
100141 The present disclosure may be better understood by referring to the
following non-
limiting figures.
[0015] Figure 1 depicts an indicator phage construct according to an
embodiment of the
disclosure illustrating the insertion of a genetic construct comprising a
promoter, RBS, and
indicator gene (soluble HiBiT) inserted into a TSP12 bacteriophage downstream
of the major
capsid protein.
[00.16] Figure 2 depicts an indicator phage construct
according to an embodiment of the
disclosure illustrating the insertion of a genetic construct comprising a
linker, IIRV 3C site, and
indicator gene (HiRiT) inserted into a TSP12 bacteriophage downstream of the
major capsid
protein.
[0017] Figure 3 depicts an indicator phage construct according to an
embodiment of the
disclosure illustrating the insertion of a genetic construct comprising a
linker, PS protease site,
and indicator gene (HiBiT) inserted into a TSPI2 bacteriophage on the N-
terminus of the Soc
protein.
4
CA 03150337 2022-3-7
WO 2021/050939
PCT/US2020/050490
100181 Figure 4 provides a table detailing homologous recombination constructs
made using
parental phage: TSP I, TSP12, SEA1, and 17 Select according to an embodiment
of the
disclosure.
100/91 Figure 5 illustrates optimization of TSPl.sHiBiT
phage concentration for detection of
Salmonella typhithurium with a 2 hour incubation in accordance with an
embodiment of the
disclosure.
100201 Figure 6 illustrates optimization of TSPl.sHiBiT
phage concentration for detection of
Salmonella typhinturiton with a 3 hour incubation in accordance with an
embodiment of the
disclosure.
100211 Figure 7 illustrates optimization of TSP12.sHiBiT phage
concentration for detection
of' Salmonella bongori with a 2 hour incubation in accordance with an
embodiment of the
disclosure.
[0022] Figure 8 illustrates optimization of TSP12.sHiBiT
phage concentration for detection
of Salmonella bongori with a 4 hour incubation in accordance with an
embodiment of the
disclosure.
100231 Figure 9 illustrates optimization of TSP12.HiBiT-PS-Soc phage
concentration for
detection of Salmonella bongori with a 2 hour incubation in accordance with an
embodiment of
the disclosure.
[0024] Figure 10 illustrates the level of detection of
TSP12.HiBiT-PS-Soc phage for
Salmonella bongori with a 2 hour incubation in accordance with an embodiment
of the
disclosure.
DETAILED DESCRIPTION OF THE DISCLOSURE
100251 Disclosed herein are compositions, methods and
systems that demonstrate surprising
sensitivity for detection of a microorganism of interest, such as Escherichia
coil, Cronobacter
spp., Salmonella spp., Listeria spp., or Staphylococcus spp., in test samples
(es., biological,
food, water, and environmental). Detection can be achieved in a shorter
timeframe than was
previously thought possible using genetically modified infectious agents in
assays performed
5
CA 03150337 2022-3-7
WO 2021/050939
PCT/US2020/050490
without culturing for enrichment, or in some embodiments with minimal
incubation times during
which microorganisms could potentially multiply_ Also surprising is the
success of using a
potentially high multiplicity of infection (MOD, or high concentrations of
plaque forming units
(PFU), for incubation with a test sample. Such high phage concentrations
(PFU/mL) were
previously purported to be detrimental in bacterium detection assays, as they
were purported to
cause "lysis from without" However, a high concentration of phage can
facilitate finding,
binding, and infecting a low number of target cells.
[0026] The compositions, methods, systems and kits of the disclosure may
comprise
infectious agents for use in detection of microorganisms such as Escherichia
cold, Cronohacter
spp., Salmonella spp.,Listeria spp., or Staphylococcus spp. a recombinant
indicator
bacteriophage comprising an indicator gene inserted into the bacteriophage
genoine, wherein the
indicator gene encodes a peptide subunit of an indicator protein. In certain
embodiments,
expression of the indicator gene during bacteriophage replication following
infection of a host
bacterium results in production of a soluble peptide subunit of an indicator
protein. In alternative
embodiments, of a fused peptide subunit of an indicator protein. In certain
embodiments, the
indicator gene may be inserted into a late gene (i.e., class III) region of
the bacteriophage.
[0027] In some embodiments, the disclosure comprises a
method for detecting a particular
bacteria of interest in a sample comprising the steps of incubating the sample
with a recombinant
indicator bacteriophage comprising an indicator gene, wherein the indicator
gene encodes a first
subunit of an indicator protein, thereby producing an amount of progeny phage
expressing the
first subunit; lysing the amount of progeny phage; incubating the lysed
progeny phage in the
presence of a detection reagent, wherein the detection reagent comprises a
second subunit of an
indicator protein, thereby allowing the first subunit and second subunit to
reconstitute to form an
indicator protein complex; and detecting the indicator protein complex,
wherein positive
detection of the indicator protein complex indicates that the particular
bacteria of interest is
present in the sample.
[0028] In certain embodiments, the disclosure may comprise a system. The
system may
contain at least some of the compositions of the disclosure. Also, the system
may comprise at
least some of the components for performing the method. In certain
embodiments, the system is
6
CA 03150337 2022-3-7
WO 2021/050939
PCT/US2020/050490
formulated as a kit. Thus, in certain embodiments, the disclosure may comprise
a system for
rapid detection of a particular bacteria of interest in a sample, comprising:
a component for
incubating the sample with an infectious agent specific for the microorganism
of interest,
wherein the infectious agent comprises an indicator moiety; and a component
for detecting the
indicator moiety. In yet other embodiments, the disclosure comprises software
for use with the
methods or systems.
[0029] Thus, some embodiments of the present disclosure solve a need by using
bacteriophage-based methods for amplifying a detectable signal indicating the
presence of
bacteria. In certain embodiments as little as a single bacterium is detected.
The principles
applied herein can be applied to the detection of a variety of microorganisms.
Because of
numerous binding sites for an infectious agent on the surface of a
microorganism, the capacity to
produce one hundred or more agent progeny during infection, and the potential
for high level
expression of an encoded indicator moiety, the infectious agent or an
indicator moiety can be
more readily detectable than the microorganism itself. In this way,
embodiments of the present
disclosure can achieve treiliendous signal amplification from even a single
infected cell.
[0030] Aspects of the present disclosure utilize the high
specificity of binding agents that can
bind to particular microorganisms, such as the binding component of infectious
agents, as a
means to detect and/or quantify the specific microorganism in a sample. In
some embodiments,
the present disclosure utilizes the high specificity of infectious agents such
as bacteriophage.
[0031] In some embodiments, detection is achieved through an indicator moiety
associated
with the binding agent specific for the microorganism of interest. For
example, an infectious
agent may comprise a gene encoding an indicator protein or a subunit thereof.
In some
embodiments the indicator may be encoded by the infectious agent, such as a
bacteriophage, and
the bacteriophage is designated an indicator phage.
[0032] Some embodiments of the disclosure disclosed and described herein
utilize the
discovery that a single microorganism is capable of binding specific
recognition agents, such as
phage_ Following infection and replication of the phage, progeny phage may be
detected via an
indicator gene expressed during phage replication. This principle allows
amplification of
indicator signal from one or a few cells based on specific recognition of
microorganism surface
7
CA 03150337 2022-3-7
WO 2021/050939
PCT/US2020/050490
receptors. For example, by exposing even a single cell of a bacterium to a
plurality of phage,
thereafter allowing amplification of the phage and high-level expression of an
encoded indicator
gene product, or subunit of an indicator protein, during replication, the
indicator signal is
amplified such that the single bacterium is detectable.
[0033] Embodiments of the methods and systems of the disclosure can be applied
to detection
and quantification of a variety of microorganisms (e.g., bacteria) in a
variety of circumstances,
including but not limited to detection of pathogens from food, water, and
commercial samples.
The methods of the present disclosure provide high detection sensitivity and
specificity rapidly_
In some embodiments detection is possible within a single replication cycle of
the bacteriophage,
which is unexpected_
Definitions
[0034] Unless otherwise defined herein, scientific and
technical terms used in connection
with the present disclosure shall have the meanings that are commonly
understood by those of
ordinary skill in the art Further, unless otherwise required by context,
singular terms shall
include pluralities and plural terms shall include the singular_ Generally,
nomenclatures used in
connection with, and techniques of, cell and tissue culture, molecular
biology, immunology,
microbiology, genetics and protein and nucleic acid chemistry and
hybridization described herein
are those well-known and commonly used in the art Known methods and techniques
are
generally performed according to conventional methods well known in the art
and as described
in various general and more specific references that are discussed throughout
the present
specification unless otherwise indicated. Enzymatic reactions and purification
techniques are
performed according to manufacturer's specifications, as commonly accomplished
in the art or as
described herein. The nomenclatures used in connection with the laboratory
procedures and
techniques described herein are those well-known and commonly used in the art.
100351 The following terms, unless otherwise indicated,
shall be understood to have the
following meanings:
8
CA 03150337 2022-3-7
WO 2021/050939
PCT/US2020/050490
[0036] As used herein, the terms "a", "an", and "the" can refer to one or more
unless
specifically noted otherwise.
[0037] The use of the term "or" is used to mean "and/or"
unless explicitly indicated to refer to
alternatives only or the alternatives are mutually exclusive, although the
disclosure supports a
definition that refers to only alternatives and "andlor." As used herein
"another" can mean at
least a second or more.
[0038] Throughout this application, the term "about" is
used to indicate that a value includes
the inherent variation of error for the device, the method being employed to
determine the value,
or the variation that exists among samples.
100391 As used herein, "solid support" or "support" means a structure that
provides a
substrate and/or surface onto which biomolecules may be bound. For example, a
solid support
may be an assay well (i.e., such as a rnicrotiter plate or multi-well plate),
or the solid support
may be a location on a filter, an array, or a mobile support, such as a bead
or a membrane (e.g,, a
filter plate, latex particles, paramagnetic particles, or lateral flow strip).
[0040] As used herein, "binding agent" refers to a molecule that can
specifically and
selectively bind to a second (i.e., different) molecule of interest. The
interaction may be non-
covalent, for example, as a result of hydrogen bonding, van der Waals
interactions, or
electrostatic or hydrophobic interactions, or it may be covalent. The term
"soluble binding
agent" refers to a binding agent that is not associated with (i.e., covalently
or non-covalently
bound) to a solid support.
[0041] As used herein, the term "bioluminescence" refers to production and
emission of light
by a chemical reaction catalyzed by, or enabled by, an enzyme, protein,
protein complex, or
other biornolecule (e.g., bioluminescent complex). In typical embodiments, a
substrate for a
bioluminescent entity (e.g., bioluminescent protein or bioluminescent complex)
is converted into
an unstable form by the bioluminescent entity; the substrate subsequently
emits light.
[0042] As used herein the term "complementary" refers to the characteristic of
two or more
structural elements (e.g., peptide, polypeptide, nucleic acid, small molecule,
etc.) of being able to
hybridize, dimerize, or otherwise form a complex with each other_ For example,
a
9
CA 03150337 2022-3-7
WO 2021/050939
PCT/US2020/050490
"complementary peptide and polypeptide" are capable of coming together to form
a complex.
Complementary elements may require assistance to form a complex (e.g., from
interaction
elements), for example, to place the elements in the proper conformation for
co-mplementarity, to
co-localize complementary elements, to lower interaction energy for
complementary, etc.
[0043] As used herein, the term "complex" refers to an assemblage or aggregate
of molecules
(e.g., peptides, polypeptides, etc.) in direct and/or indirect contact with
one another. In one
aspect, "contact," or more particularly, "direct contact" means two or more
molecules are close
enough so that attractive non-covalent interactions, such as Van der Waal
forces, hydrogen
bonding, ionic and hydrophobic interactions, and the like, dominate the
interaction of the
molecules. In such an aspect, a complex of molecules (e.g., a peptide and
polypeptide) is formed
under assay conditions such that the complex is thermodynamically favored
(e.g., compared to a
non-aggregated, or non-complexed, state of its component molecules). As used
herein the term
"complex," unless described as otherwise, refers to the assemblage of two or
more molecules
(e.g., peptides, polypeptides or a combination thereof).
100441 As used herein, the term "non-luminescent" refers to an entity
(e.g., peptide,
polypeptide, complex, protein, etc.) that exhibits the characteristic of not
emitting a detectable
amount of light in the visible spectrum (e.g., in the presence of a
substrate). For example, an
entity may be referred to as non-luminescent if it does not exhibit detectable
luminescence in a
given assay. As used herein, the term "non-luminescent" is synonymous with the
term
"substantially non-luminescent. For example, a non-luminescent polypeptide is
substantially
non-luminescent, exhibiting_ for example, a 10-fold or more (e.g,, 100-fold,
200-fold, 500-fold,
1 x 10Sup3/Sup-fold, 1 xl0Sup4/Sup-fold, 1 x 10Sup5/Sup-fold, 1 x 10Sup6/Sup-
fold,
I xl0Sup7/Sup-fold, etc.) reduction in luminescence compared to a complex of
the NLpoly with
its non-luminescent complement peptide. In some embodiments, an entity is "non-
luminescent"
if any light emission is sufficiently minimal so as not to create interfering
background for a
particular assay.
[0045] As used herein, the terms "non-luminescent peptide" and "non-
luminescent
polypeptide" refer to peptides and polypeptides that exhibit substantially no
luminescence (e.g.,
in the presence of a substrate), or an amount that is beneath the noise, or a
10-fold or more (e.g.,
CA 03150337 2022-3-7
WO 2021/050939
PCT/US2020/050490
100-fold, 200-fold, 500-fold, lx I 0Sup3/Sup-fold, lx10Sup4/Sup-fold, lx
10Sup5/Sup-fold,
I xl0Sup6/Sup-fold, 1 xl0Sup7/Sup-fold, etc.) when compared to a significant
signal (e.g.,
luminescent complex) under standard conditions (e.g., physiological
conditions, assay
conditions, etc.) and voith typical instrumentation (e.g., luminometer, etc.).
In some
embodiments, such non-luminescent peptides and polypeptides assemble,
according to the
criteria described herein, to form a bioluminescent complex. As used herein, a
"non-luminescent
element" is a non-luminescent peptide or non-luminescent polypeptide. The term
"bioluminescent complex" refers to the assembled complex of two or more non-
luminescent
peptides and/or non-luminescent polypeptides. The bioluminescent complex
catalyzes or enables
the conversion of a substrate for the bioluminescent complex into an unstable
form; the substrate
subsequently emits light. When uncomplexed, two non-luminescent elements that
form a
bioluminescent complex may be referred to as a "non-luminescent pair." If a
bioluminescent
complex is formed by three or more non-luminescent peptides and/or non-
luminescent
polypeptides, the uncomplexed constituents of the bioluminescent complex may
be referred to as
a "non-luminescent group."
[0046] As used herein, an "analyte" refers to a molecule,
compound or cell that is being
measured. The analyte of interest may, in certain embodiments, interact with a
binding agent.
As described herein, the term "analyte" may refer to a protein or peptide of
interest. An analyte
may be an agonist, an antagonist, or a modulator. Or, an analyte may not have
a biological
effect. Analytes may include small molecules, sugars, oligosaccharides,
lipids, peptides,
peptidomimetics, organic compounds and the like.
[0047] As used herein, "detectable moiety" or "detectable biomolecule" or
"reporter" or
"indicator" or "indicator protein" or "indicator protein product" "indicator
protein complex" or
"indicator moiety" refers to a molecule that can be measured in a quantitative
assay. For
example, an indicator protein may comprise an enzyme that may be used to
convert a substrate to
a product that can be measured.. An indicator moiety may be an enzyme that
catalyzes a reaction
that generates bioluminescent emissions (e.g., luciferase). Or, an indicator
moiety may be a
radioisotope that can be quantified. Or, an indicator moiety may be a
fluorophore. Or, other
detectable molecules may be used.
11
CA 03150337 2022-3-7
WO 2021/050939
PCT/US2020/050490
100481 As used herein, "bacteriophage" or "phage" includes one or more of a
plurality of
bacterial viruses. In this disclosure, the terms "bacteriophage" and "phage"
include viruses such
as mycobacteriophage (such as for TB and paraTB), mycophage (such as for
fungi), mycoplastna
phage, and any other term that refers to a virus that can invade living
bacteria, fungi,
naycoplasnaa, protozoa, yeasts, and other microscopic living organisms and
uses them to replicate
itself. Here, "microscopic" means that the largest dimension is one millimeter
or less_
Bacteriophages are viruses that have evolved in nature to use bacteria as a
means of replicating
themselves. A phage does this by attaching itself to a bacterium and injecting
its DNA (or RNA)
into that bacterium, and inducing it to replicate the phage hundreds or even
thousands of times.
This is referred to as phage amplification.
[0049] As used herein, "late gene region" refers to a region of a viral genome
that is
transcribed late in the viral life cycle. The late gene region typically
includes the most
abundantly expressed genes (e.g., structural proteins assembled into the
hacteriophage
particle). Late genes are synonymous with class III genes and include genes
with structure and
assembly functions. For example, the late genes (synonymous with class IIIõ)
are transcribed in
phage T7, e.g., from 8 minutes after infection until lysis, class I (e.g., RNA
polymerase) is early
from 4-8 minutes, and class H from 6-15 minutes, so there is overlap in timing
of!! and III. A
late promoter is one that is naturally located and active in such a late gene
region.
[0050] As used herein, "culturing for enrichment" refers
to traditional culturing, such as
incubation in media favorable to propagation of microorganisms, and should not
be confused
with other possible uses of the word "enrichment," such as enrichment by
removing the liquid
component of a sample to concentrate the microorganism contained therein, or
other forms of
enrichment that do not include traditional facilitation of microorganism
propagation. Culturing
for enrichment for periods of time may be employed in some embodiments of
methods described
herein.
[0051] As used herein "recombinant" refers to genetic
(i.e., nucleic acid) modifications as
usually performed in a laboratory to bring together genetic material that
would not otherwise be
found. This term is used interchangeably with the term "modified" herein.
12
CA 03150337 2022-3-7
WO 2021/050939
PCT/US2020/050490
100521 As used herein "RLU" refers to relative light units as measured by a
luminometer
(e.g., GLOMAX 96) or similar instrument that detects light. For example, the
detection of the
reaction between luciferase and appropriate substrate (e.g., NANOLUC with
NANO-GLOk) is
often reported in RLU detected..
100531 As used herein "time to results" refers to the total amount of time
from beginning of
sample incubation to generated result. Time to results does not include any
confirmatory testing
time. Data collection can be done at any time after a result has been
generated.
100541 As used herein "reporter gene" or "indicator gene" may refer to a
complete gene or to
a portion of a gene. For example, the use of indicator gene or reporter gene
herein may include a
nucleotide sequence that encodes a smaller peptide subunit, i.e._ that is
transcribed and translated
into a partial protein.
Samples
100551 Each of the embodiments of the methods and systems of the disclosure
can allow for
the rapid detection and quantification of microbes in a sample. For example,
methods according
to the present disclosure can be performed in a shortened time period with
superior results.
100561 Microbes detected by the methods and systems of the present invention
include
pathogens that are of natural, commercial, medical or veterinary concern. Such
pathogens include
Gram-negative bacteria, Gram-positive bacteria, and mycoplasmas. Any microbe
for which an
infectious agent that is specific for the particular microbe has been
identified can be detected by
the methods of the present invention. Those skilled in the art will appreciate
that there is no limit
to the application of the present methods other than the availability of the
necessary specific
infectious agent/microbe pairs_
100571 Bacterial cells detectable by the present
disclosure include, but are not limited to,
bacterial cells that are food or water borne pathogens. Bacterial cells
detectable by the present
invention include, but are not limited to, all species of Salmonella, all
strains of Escherichia colt,
Cronobacter, Staphylococcus, all species of Listeria, including, but not
limited to L.
monocytogenes, and all species of Campylobacter Bacterial cells detectable by
the present
13
CA 03150337 2022-3-7
WO 2021/050939
PCT/US2020/050490
invention include, but are not limited to, bacterial cells that are pathogens
of medical or
veterinary significance. Such pathogens include, but are not limited to,
Bacillus spp., Bordetella
pertussis, Camplyobacierfejuni, Chlatnydia pneumoniae, Clostridium
petfringens, Enterobacter
spp., Klebsiella pneumoniae, Mycoplasma pneumonkte, Mitnonella
Shigella sonnei,
Staphylococcus auretts, and Streptococcus spp. In some embodiments, bacterial
cells detectable
by the present invention include antibiotic-resistant bacteria (e.g.,
methicillin-resistant
Staphylococcus aureus (MRSA).
[0058] The sample may be an environmental or food or water sample. Some
embodiments
may include medical or veterinary samples. Samples may be liquid, solid, or
semi-solid.
Samples may be swabs of solid surfaces. Samples may include environmental
materials, such as
the water samples, or the filters from air samples or aerosol samples from
cyclone collectors.
Samples may be of vegetables, meat, fish, poultry, peanut butter, processed
foods, powdered
infant formula, powdered milk, teas, starches, eggs, milk, cheese, or other
dairy products.
Medical or veterinary samples include, but are not limited to, blood, sputum,
cerebrospinal fluid,
and fecal samples and different types of swabs.
[0059] In some embodiments, samples may be used directly in the detection
methods of the
present disclosure, without preparation, concentration, or dilution. For
example, liquid samples,
including but not limited to, milk and juices, may be assayed directly.
Samples may he diluted
or suspended in a solution, which may include, but is not limited to, a
buffered solution or a
bacterial culture medium. A sample that is a solid or semi-solid may be
suspended in a liquid by
mincing, mixing or macerating the solid in the liquid. A sample should be
maintained within a
pH range that promotes bacteriophage attachment to the host bacterial cell. A
sample should
also contain the appropriate concentrations of divalent and monovalent
cations, including but not
limited to Na+, Mg2+, and Ca2t. Preferably, a sample is maintained at a
temperature that supports
the viability of any pathogen cells contained within the sample.
[0060] Preferably throughout detection assays, the sample
is maintained at a temperature that
maintains the viability of any pathogen cell present in the sample. During
steps in which
bacteriophages are attaching to bacterial cells, it is preferable to maintain
the sample at a
temperature that facilitates bacteriophage attachment. During steps in which
bacteriophages are
14
CA 03150337 2022-3-7
WO 2021/050939
PCT/US2020/050490
replicating within an infected bacterial cell or lysing such an infected cell,
it is preferable to
maintain the sample at a temperature that promotes bacteriophage replication
and lysis of the
host. Such temperatures are at least about 25 degrees Celsius (C), more
preferably no greater
than about 45 degrees C, most preferably about 37 degrees C.
[0061] Assays may include various appropriate control samples. For example,
control
samples containing no bacteriophages or control samples containing
bacteriophages without
bacteria may be assayed as controls for background signal levels.
Indicator Bacteriophage
[0062] As described in more detail herein, the compositions, methods, systems
and kits of the
invention may comprise infectious agents for use in detection of pathogenic
microorganisms. In
certain embodiments, the present disclosure comprises a recombinant indicator
bacteriophage.,
wherein the bacteriophage genome is genetically modified to include an
indicator or reporter
gene. In some embodiments, the invention may include a composition comprising
a recombinant
bacteriophage having an indicator gene incorporated into the genome of the
bacteriophage,
wherein the indicator gene encodes a peptide subunit of an indicator protein.
[0063] A recombinant indicator bacteriophage can include a reporter or
indicator gene or an
indicator peptide subunit. In some embodiments of the indicator bacteriophage,
the indicator or
peptide subunit gene encodes a fusion protein. For example, the indicator or
indicator peptide
subunit may be fused with a bacteriophage capsid protein, such that the
indicator is expressed as
part of the bacteriophage capsid. The indicator may also be fused with another
protein for
production as a soluble molecule. In other embodiments of the indicator
bacteriophage, the
indicator gene does not encode a fusion protein_ For example, in certain
embodiments,
expression of the indicator gene during bacteriophage replication following
infection of a host
bacterium results in a non-fusion soluble indicator protein product. In
certain embodiments, the
indicator or indicator peptide or polypeptide subunit gene may be inserted
into a late gene region
of the bacteriophage. Late genes are generally expressed at higher levels than
other phage genes,
CA 03150337 2022-3-7
WO 2021/050939
PCT/US2020/050490
as they code for structural proteins. The late gene region may be a class III
gene region and may
include a gene for a major capsid protein.
[0064] Some embodiments include designing (and optionally preparing) a
sequence for
homologous recombination downstream of the major capsid protein gene. Other
embodiments
include designing (and optionally preparing) a sequence for homologous
recombination upstream
of the major capsid protein gene. In some embodiments, the sequence comprises
a codon-
optimized reporter gene preceded by an untranslated region. The untranslated
region may
include a phage late gene promoter and ribosomal entry site.
[0065] In some embodiments, an indicator bacteriophage is
derived from the selected wild-
type bacteriophage Salmonella phage SPN1S, Salmonella phage 10, Salmonella
phage
epsilon IS. Salmonella phage SEAlõcalmonella phage TSP I , Salmonella phage
TSP12,
Salmonella phage Spills, Salmonella phage P22, Listeria phage LipZ5, Listeria
phage P40,
Listeria phage vB_LmoM_A620, Listeria phage P70, Listeria phage A511, Listeria
phage P100,
Listeria phage LMA8, Listeria phage LMA4, Staphylococcus phage P4W.
Staphylococcus phage
K, Staphylococcus phage Twort, Staphylococcus phage SA97, Escherichict coli
0157:H7 phage
CBA120, or another bacteriophage having a genome with at least 70, 71, 72, 73,
74, 75, 76, 77,
78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92,93, 94, 95, 96, 97,
98, or 99 A homology
to the selected wild-type bacteriophage Salmonella phage SPN1S, Salmonella
phage 10,
Salmonella phage epsilon15, Salmonella phage SEA1, Salmonella phage TSP 1,
Salmonella
phase TSP12, Salmonella phage Spnl s, Salmonella phage P22, Listeria phase
LipZ5, Listeria
phage P40, Listeria phage vB_LmoM_AG20, Listeria phage P70, Listeria phage
A511,
Staphylococcus phage P4W, Staphylococcus phage K, Staphylococcus phage Twort,
Staphylococcus phage SA97, or Escherichia colt 0157:H7 phage CBA120. In some
embodiments, the indicator phage is derived from a bacteriophage that is
highly specific for a
particular pathogenic microorganism. The genetic modifications may avoid
deletions of wild-
type genes and thus the modified phage may remain more similar to the wild-
type infectious
agent than many commercially available phage. Environmentally derived
bacteriophage may be
more specific for bacteria that are found in the environment and as such,
genetically distinct from
phase available commercially.
16
CA 03150337 2022-3-7
WO 2021/050939
PCT/US2020/050490
100661 In some embodiments, the recombinant bacteriophage comprises a binding
domain
having 95% homology to the binding domain of any of the following
bacteriophages:
Salmonella phage SPN is, Salmonella phage IO, Salmonella phase epsilon15,
Salmonella phage
SEA1, Salmonella phage TSP1, Salmonella phage TSP12, Salmonella phage Spnls,
Salmonella
phage P22, Lisieria phage LipZ5, Listeria phage P40, Listeria phage
vB_LmoM_AG20, Listeria
phage P70, Listeria phage A511, Staphylococcus phage P4W, Staphylococcus phage
K,
Staphylococcus phage Twort, Staphylococcus phage SA97, or Escherichia coil
0157-.H7 phage
CBAI20.
100671 In certain instances, the indicator phage is
derived from a bacteriophage that is highly
specific for a particular pathogenic microorganism. In some embodiments the
indicator phage is
derived from T7SeIect. T7Select is a commercially available phage display
system from
Novagen_ T7 is a well characterized prototypical phage infecting Escherichia
from the
Podoviridae family. The capsid of T7 phage is comprised of 9:1 ratio of the 2
isoforms of MCP
(gplOa and gplOb). The gplOa and gplOb arise from a frame shift in translation
and this shift
can be modulated to yield different ratios of the gplOa:gplOb isofonns.
T7Select is a cloning
plasmid containing the entire T7 genome. A peptide or protein of a certain
length can be cloned
into the C-terminus of the gplOb and expressed in high (415) medium (5-10) or
low (up to 1)
copy number per bacteriophage.
[0068] In some embodiments, the indicator phage is derived from TSP12, a
Salmonella phage
specific to Salmonella hongori strains. This phage is most closely related to
Enterobacteria
R1351 Phage which belongs to the Tequatrovirus genus. This genus includes the
well
characterized and studied Escherichia T4 virus. This phage has a number of
capsid structures
published detailing protein components and conformations. TSP12 has several
structural
candidate genes for tagging with a peptide or polypeptide labeling subunit,
including but not
limited to the Major Capsid Protein (gp23) and accessory small outer capsid
protein (gpSoc).
100691 In some embodiments, the indicator phage is derived from, SEA], a
Salmonella
phage. SEA' is most closely related to Salmonella phage vB SenM-S16 of the
genus
Gelderlandvirus [GenBank: HQ 331142.1]. SEA1 has several structural candidate
genes for
tagging with a peptide or polypeptide labeling subunit, including but not
limited to the major
17
CA 03150337 2022-3-7
WO 2021/050939
PCT/US2020/050490
eapsid protein, head vertex protein, head outer capsid protein and small outer
capsid protein. The
major capsid protein can be tagged on either the amino(N) or carboxy (C)
termini.
[0070] In some embodiments, the indicator phage is derived from TSP1, a
Salmonella phage.
TSP I is most closely related to the Scutionella and Escherichia Kattervints
genus of phage. The
TSP1 phage has at least one candidate gene for tagging with a peptide or
polypeptide labeling
subunit, including but not limited to, a single major prohead protein.
100711 The genetic modifications may avoid deletions of wild-type genes and
thus the
modified phage may remain more similar to the wild-type infectious agent than
many
commercially available phage. Environmentally derived bacteriophage may be
more specific for
bacteria that are found in the environment and as such, genetically distinct
from phage available
commercially.
100721 Moreover, phage genes thought to be nonessential may have unrecognized
function.
For example, an apparently nonessential gene may have an important function in
elevating burst
size such as subtle cutting, fitting, or trimming functions in assembly.
Therefore, deleting genes
to insert an indicator may be detrimental. Most phages can package a DNA that
is up to ten
percent -larger than their natural genome. Different viruses, including
phages, have varying burst
sizes. Burst sizes are heavily dependent on the host, multiplicity of
infection (MOD, and growth
conditions. Phage lambda and other phages (such as T4, T5 and T7) have burst
sizes of about
100-300. In some embodiments, the selected bacteriophage has a burst size of
at least 25, 50, 75,
100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 250, 375, 400, 425, 450,
475, or 500 Pal/cell.
For example, T7 has a burst size of 180 PFU/oell; T4 has a burst size of 130
PHI/cell; and
CBA120 has a burst size of 440 PFUkell. A smaller burst size means less
progeny phage are
available for production of an indicator protein product_ Thus, the use of a
phage with a larger
burst size is advantageous in amplifying the signal and increasing assay
sensitivity.
[0073] Small phage pack smaller genomes, and therefore, have less tolerance
for additional
transgenes. Another possible advantage to a small reporter gene is that it may
be expressed at
higher numbers, as each copy of the protein requires fewer finite cellular
resources_ Yet, the
HiBiT tag alone may be too small to be properly expressed, or properly fold.
18
CA 03150337 2022-3-7
WO 2021/050939
PCT/US2020/050490
[0074] With these considerations, a smaller indicator gene may be a more
appropriate choice
for modifying a bacteriophage, especially a bacteriophage with a smaller
genome. OpLuc and
NANOLUC proteins are only about 20 kDa (approximately 500-600 bp to encode),
while FLuc
is about 62 kDa (approximately 1,700 bp to encode). For comparison, the genome
of T7 is
around 40 kbp, while the T4 genome is about 170 kbp. In some embodiments, the
indicator gene
encodes a subunit of a reporter protein (e.g., NANOLUCS). In some embodiments,
the use of a
smaller indicator gene (e.g., a subunit of indicator protein) allows for
multiple copies of the
indicator gene to be inserted into the phage genome, thereby further
amplifying the signal.
100751 Protein complementation assays (PCA) provide a means to detect the
interaction of
two biomolecules, e.g., polypeptide subunits. PCAs may utilize two subunits of
the same protein,
e.g., enzyme, that when brought into close proximity with each other can
reconstitute into a
functional, active protein. PCAs involve the use of at least two subunits of a
protein to detect a
protein of interest. Thus, in some embodiments of the recombinant indicator
bacteriophage, the
indicator gene encodes one subunit of a split reporter protein. In certain
instances, the split
reporter protein is a functional enzyme (e.g., a luciferase or a 13-
galactosidase). In further
embodiments, the luciferase is NANOLUC . In some embodiments, the split
reporter (indicator
protein) comprises a first polypeptide subunit (labeling subunit) and a second
polypeptide
subunit (detection subunit). In still further embodiments, the labeling
subunit is complementary
to the detection subunit. In certain instances, the labeling subunit is
capable of binding the
detection subunit to form an indicator protein complex. Thus, in some
embodiments of the
recombinant indicator bacteriophage, an indicator gene inserted into the
bacteriophage genome,
wherein the indicator gene encodes a polypeptide subunit (labeling subunit) of
an indicator
protein.
[0076] In certain embodiments of the indicator phage, a
gene encoding the labeling subunit is
inserted into the phage genome. In further embodiments, the indicator gene
during
bacteriophage replication following infection of the bacterium of interest
results in production of
an indicator protein product allowing for protein-protein interactions with a
second subunit
(detection subunit). In some embodiments, the labeling subunit encounters the
detection subunit
to form a functional enzyme (e.g., luciferase). In further embodiments, the
functional enzyme
19
CA 03150337 2022-3-7
WO 2021/050939
PCT/US2020/050490
generates a signal. In some instances, generation of a signal requires the
functional enzyme
contacts a substrate_
[0077] Figure 1 depicts a schematic representation of the
genomic structure of one
embodiment of a recombinant bacteriophage of the disclosure, Indicator Phage
TSP12.s.HiBiT.
For the embodiment depicted in Figure 1, the indicator protein is encoded by a
soluble HiBiT
gene inserted within the late (class HI) gene region, which is expressed late
in the viral life
cycle. Late genes are generally expressed at higher levels than other phase
genes, as they code
for structural proteins. Thus, in the embodiment of the recombinant phage
depicted by Figure!,
the indicator gene (i.e., soluble HiBiT) is inserted into the late gene
region, just after the major
capsid protein (MCP) gene, and is a construct comprising the HiBiT luciferase
gene. Also as
depicted by Figure 1, the construct may comprise a late promoter to drive
transcription and
expression of the HiBiT gene_ The construct may also comprise a composite
untranslated region
synthesized from several UTRs and stop codons in all 3 reading frames to
ensure HiBiT is not
incorporated into the MCP gene product. This construct ensures soluble HiBiT
is produced such
that expression is not limited to the number of capsid proteins inherent in
the phage display
system.
[0078] Figure 2 depicts a schematic representation of the
genomic structure of a recombinant
bacteriophage of the disclosure, Indicator Phage TSP12.MCP-PS-HiBiT. For the
embodiment
depicted in Figure 2, a HiBiT gene is inserted at the C-terminus of the MCP to
generate a MCP-
HiBiT fusion protein_ The MCP is located within the late (class 111) gene
region, which is
expressed late in the viral life cycle. Late genes are generally expressed at
higher levels than
other phage genes, as they code for structural proteins. Thus, in the
embodiment of the
recombinant phage depicted by Figure 2, the indicator gene (i.e., HiBiT) is
inserted into the late
gene region, at the C-terminus of the MCP gene, and is a construct comprising
the HiBiT
Iuciferase gene. Also as depicted by Figure 2, the construct may comprise a
linker and HRV 3C
protease cut site. The HRV 3C protease cut site allows for HiBit to be removed
from the phage
during phage preparation.
[0079] In some embodiments, the NANO-GLO HiBiT Detection System (Promega
Corporation) may be used to detect molecular proximity by virtue of the
reconstitution of a
CA 03150337 2022-3-7
WO 2021/050939
PCT/US2020/050490
luminescent enzyme via the binding interaction of enzyme components or
subunits. The NANO-
GLO HiBiT Detection System utilizes a peptide tag (HiBiT) and a polypeptide
(LgBiT)
derived from the Oplophorus lueiferase variant, NANOLUC . In some embodiments,
HiBiT (11
amino acids) is the labeling subunit and LgBiT (156 amino acids) is the
detection subunit. Thus,
in some embodiments, the indicator phage comprises an indicator gene, wherein
the indicator
gene is HiBiT. When the HiBiT peptide encounters the LgBiT peptide, they
reconstitute to form
a ftill-length, functional luciferase enzyme. In some embodiments, the
detection reagent
comprises the complementing polypeptide, LgBiT, which spontaneously interacts
with the HiBiT
tag to reconstitute a bright, luminescent enzyme. enzyme. In some embodiments,
the indicator
protein complex is combined with Promega's NANO-GLOO, an imidazopyrazinone
substrate
(furimazine), can provide a robust signal_ with low background. In some
embodiments, the
detection reagent comprises NANO-GLOO.
[0080] In some embodiments, the detection subunit has a
high affinity for the labeling
subunit. In further embodiments, the labeling subunit is capable of binding to
the detection
subunit to from an indicator complex. HiBiT binds tightly to LgBiT, thus,
promoting formation
of a luciferase indicator complex. In some embodiments, the binding affinity
(equilibrium
dissociation constant (Kn)) between the labeling subunit and the detection
subunit is at least 0.2,
0,3, 0,4, 0.5, 0,6, 0.7, 0.8, 0.9, or 1.0 nM,
[0081] In some embodiments, each subunit exhibits little
to no reporter activity. In certain
embodiments, the labeling subunit and the detection subunit are non-
luminescent or substantially
non-luminescent. In other embodiments, the labeling subunit is luminescent.
Moreover, the
reporter gene should not be expressed endogenously by the bacteria (i.e., is
not part of the
bacterial genome), should generate a high signal to background ratio, and
should be readily
detectable in a timely manner.
[0082] In some embodiments, the gene encoding the labeling subunit is inserted
into an
indicator bacteriophae-e genome. In certain embodiments, the labeling subunit
forms a fusion
protein with a phage structural protein. These proteins are the most abundant
proteins made by
the phage, as each bacteriophage particle comprises dozens or hundreds of
copies of these
molecules. In some embodiments, the labeling subunit is fused to a phage
capsid protein. In
21
CA 03150337 2022-3-7
WO 2021/050939
PCT/US2020/050490
other embodiments, the labeling subunit is fused to a phage tail fiber
protein. In certain
embodiments, the gene encoding the labeling subunit is inserted into a late
gene region of the
bacteriophage. The late gene region may be a class HI gene region and may
include a gene for a
major capsid protein. In some embodiments, the labeling subunit forms a fusion
protein with a
capsid protein. For example, the labeling subunit may be fused to the major
capsid protein. The
major capsid protein is present in multiple copies on the bacteriophage. For
example, T4 phage
have approximately 1,000 copies of the major capsid protein, thus allowing for
further
amplification of the signal.
100831 Reporter systems can be problematic in that they can impact proteins
with which they
interact. In some embodiments, the reporter system has minimal steric burden
on its fusion
partners. In further embodiments, the reporter system has minimal influence on
the affinity and
association kinetics of the interacting target proteins_ In some embodiments,
each subunit has
been structurally optimized. In certain embodiments, the labeling subunit is
small, so that steno
conflicts on fusion partners are minimized. In some instances, the detection
subunit is optimized
for stability. In some embodiments, it is advantageous for the labeling
subunit to be smaller than
the detection subunit. Thus, in certain embodiments the labeling subunit is
less than 50, 40, 30,
20, 15, 10, or 5 amino acids long. In further embodiments, the detection
subunit is at least 50,
60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210,
220, 230, 240, or 250
amino acids long.
[0084] Genetic modifications to infectious agents may inc bide insertions,
deletions, or
substitutions of a small fragment of nucleic acid, a substantial part of a
gene, or an entire gene.
In some embodiments, inserted or substituted nucleic acids comprise non-native
sequences. A
non-native indicator gene may be inserted into a bacteriophage genome such
that it is under the
control of a bacteriophage promoter. Thus, in some embodiments, the non-native
indicator gene
is not part of a fusion protein. That is, in some embodiments, a genetic
modification may be
configured such that the indicator protein product does not comprise
polypeptides of the wild-
type bacteriophage. In some embodiments, the indicator protein product is
soluble. In some
embodiments, the disclosure comprises a method for detecting a bacterium of
interest comprising
the step of incubating a test sample with such a recombinant bacteriophage.
22
CA 03150337 2022-3-7
WO 2021/050939
PCT/US2020/050490
10085] In some embodiments, expression of the indicator gene in progeny
bacteriophage
following infection of host bacteria results in a free, soluble protein
product In some
embodiments, the non-native indicator gene is not contiguous with a gene
encoding a structural
phage protein and therefore does not yield a fusion protein. In certain
instances, it is
advantageous to employ a non-fusion protein system. For example, a fusion
protein would
require the indicator peptide first be cleaved off proteolytically, prior to
purification of the phage
particles from the peptide tag (e.g., HiBiT) in the stock lysate. Unlike
systems that employ a
fusion of an indicator protein to the capsid protein (i.e., a fusion protein),
some embodiments of
the present invention express a soluble indicator or reporter (e.g., soluble
lueiferase). In some
embodiments, the indicator or reporter is ideally free oldie bacteriophage
structure_ That is, the
indicator or reporter is not attached to the phage structure. As such, the
gene for the indicator or
reporter is not fused with other genes in the recombinant phase genome. This
may greatly
increase the sensitivity of the assay (down to a single bacterium), and
simplifies the assay,
allowing the assay to be completed in less than an hour for some embodiments,
as opposed to
several hours due to additional purification steps required with constructs
that produce detectable
fusion proteins. Further, fusion proteins may be less active than soluble
proteins due, e.g., to
protein folding constraints that may alter the conformation of the enzyme
active site or access to
the substrate.
[0086] In other embodiments, the fused protein comprising a labeling unit is
expressed in
progeny bacteriophage following infection of host bacteria. In certain
instances, the labeling
subunit gene is contiguous with a gene encoding a structural phage protein and
therefore yields a
fusion protein. Fusion proteins may result in folding constraints that may
alter the conformation
of the enzyme active site or access to the substrate.
10087] In order to keep the advantages of a non-fusion
protein system, and keep the
transgene insert small, in some embodiments, the peptide or polypeptide tag
(e.g., HiBiT) is
fused to a small protein, which may act as a stabilization domain. This can be
accomplished by
fusing the peptide tag (e.g., HiBiT) to truncated versions of known larger
proteins, or fusing the
peptide tag (e.g., HiBiT) to known small proteins. For example, small proteins
include the 6.5
kDa a-protinin (encoded by 177 nucleotides) or the 14 IcaDa alpha lactalbumin
(encoded by 372
23
CA 03150337 2022-3-7
WO 2021/050939
PCT/US2020/050490
nucleotides). In certain embodiments, a short amino acid linker is present
between the
domains. Even with the linker region (e.g., HiBiT with a gly-ser-gly-ser
linker is 48 nucleotides
long), these soluble fusion protein genes would be smaller than other
luminescent proteins
known in the art (e.g., the 516 nucleotide long NANOLUC ). In some
embodiments, the
indicator phage encodes a subunit of a reporter, such as a detectable enzyme.
The reporter
(indicator complex) may generate light and/or may be detectable by a color
change. Various
appropriate enzymes are commercially available, such as alkaline phosphatase
(AP), horseradish
peroxidase (HRP), or luciferase (Luc). In some embodiments, these enzymes may
serve as the
reporter. In some embodiments, Firefly luciferase is the reporter. In some
embodiments,
Oplophorns luciferase is the reporter. Other engineered luciferases or other
enzymes that
generate detectable signals may also be appropriate indicator protein
products_
[0088] In some embodiments, the use of a soluble indicator
protein product eliminates the
need to remove contaminating parental phage from the lysate of the infected
sample cells. With a
fusion protein system, any bacteriophage used to infect sample cells would
have the indicator
protein product attached, and would be indistinguishable from the daughter
bacteriophage also
containing the indicator protein product. As detection of sample bacteria
relies on the detection
of a newly created (de novo synthesized) indicator protein product, using
fusion constructs
requires additional steps to separate old (parental) moieties (indicator
proteins) from newly
created (daughter bacteriophage) moieties (indicator proteins). This may be
accomplished by
washing the infected cells multiple times, prior to the completion of the
bacteriophage life cycle,
inactivating excess parental phage after infection by physical or chemical
means, and/or
chemically modifying the parental bacteriophage with a binding moiety (such as
biotin), which
can then be bound and separated (such as by streptavidin-coated sepharose
beads). However,
even with all these attempts at removal, parental phage can remain when a high
concentration of
parental phage is used to assure infection of a low number of sample cells,
creating background
signal that may obscure detection of signal from infected cell progeny phage.
[0089] By contrast, with the soluble indicator protein
products expressed in some
embodiments of the present disclosure, purification of the parental phage from
the final lysate is
unnecessary, as the parental phage do not have any indicator protein product
attached. Thus any
24
CA 03150337 2022-3-7
WO 2021/050939
PCT/US2020/050490
indicator protein product present after infection must have been created de
novo, indicating the
presence of an infected bacterium or bacteria. To take advantage of this
benefit, the production
and preparation of parental phage may include purification of the phage from
any free indicator
protein produced during the production of parental bacteriophage in bacterial
culture. Standard
bacteriophage purification techniques may be employed to purify some
embodiments of phage
according to the present invention, such as sucrose density gradient
centrifugation, cesium
chloride isopycnic density gradient centrifugation, HPLC, size exclusion
chromatography, and
dialysis or derived technologies (such as Amicon brand concentrators ¨
Millipore, Inc.). Cesium
chloride isopycnic ultracentrifugation can be employed as part of the
preparation of recombinant
phage of the invention, to separate parental phage particles from
contaminating luciferase protein
produced upon propagation of the phage in the bacterial host In this way, the
parental
recombinant bacteriophage of the invention is substantially free of any
luciferase generated
during production in the bacteria. Removal of residual luciferase present in
the phage stook can
substantially reduce background signal observed when the recombinant
bacteriophage are
incubated with a test sample.
[0090] Standard bacteriophage purification techniques may be employed to
purify some
embodiments of phage according to the present disclosure, such as sucrose
density gradient
centrifugation, cesium chloride isopycnic density gradient centrifugation,
HPLC, size exclusion
chromatography, and dialysis or derived technologies (such as Amicon brand
concentrators ¨
Millipore, Inc.). Cesium chloride isopycnic ultracentrifugation can be
employed as part of the
preparation of recombinant phage of the disclosure, to separate parental phage
particles from
contaminating luciferase protein produced upon propagation of the phage in the
bacterial host.
In this way, the parental recombinant bacteriophage of the disclosure is
substantially free of any
luciferase generated during production in the bacteria. Removal of residual
luciferase present in
the phage stock can substantially reduce background signal observed when the
recombinant
bacteriophage are incubated with a test sample.
[0091] In some embodiments, the late promoter is a T7, T4,
T4-like, Phage K, MP131,
MPI15, IvIP112, MP506, MP87, Rambo, SARIV1 promoter, or another phage promoter
similar
to that found in the selected wild-type phage, i.e., without genetic
modification. The late gene
CA 03150337 2022-3-7
WO 2021/050939
PCT/US2020/050490
region may be a class III gene region, and the bacteriophage may be derived
from T7, 14, T4-
like, Phage K, MP131, MP115, MP112, MP506, MP87, Rambo, SAPPV1, Staphylococcus-
, or S.
aureus-specific bacteriophage, or another natural bacteriophage having a
genome with at least
70, 75, 80, 85,90 or 95% homology to 17, T4, T4-like, Phace K, MP131, MP115,
MP112,
MP506, MP87, Rambo, SAPNI, Staphylococcus-, or S. aureus-specific
bacteriophage or has
high affinity for RNA polynaerase of the same bacteriophage that transcribes
genes for structural
proteins assembled into the bacteriophage particle. The use of a viral late
promoter can ensure
optimally high level of expression of the luciferase indicator protein
product. The use of a late
viral promoter derived from, specific to, or active under the original wild-
type bacteriophage the
indicator phage is derived from (e.g., a T4, T7, Vi!, or Salca late promoter
with a T4-, T7-,
or Saka-based system) can further ensure optimal expression of the indicator
protein product
The use of a standard bacterial (non-viral/non-bacteriophage) promoter may in
some cases be
detrimental to expression, as these promoters are often down-regulated during
bacteriophage
infection (in order for the bacteriophage to prioritize the bacterial
resources for phage protein
production). Thus, in some embodiments, the phage is preferably engineered to
encode and
express at high level a soluble (free) indicator protein, using a placement in
the genome that does
not limit expression to the number of subunits of a phage structural
component.
[0092] Compositions of the disclosure may comprise one or more wild-type or
genetically
modified infectious agents (e.g., bacteriophages) and one or more indicator
genes. In some
embodiments, compositions can include cocktails of different indicator phages
that may encode
and express the same or different indicator proteins. In some embodiments, the
cocktail of
bacteriophage comprises at least two different types of recombinant
bacteriophages.
Methods of Preparing Indicator Bacteriophage
[0093] Embodiments of methods for making indicator bacteriophage begin with
selection of a
wild-type bacteriophage for genetic modification. Some bacteriophage are
highly specific for a
target bacterium. This presents an opportunity for highly specific detection.
[0094] Thus, the methods of the present disclosure utilize
the high specificity of binding
agents, associated with infectious agents that recognize and bind to a
particular microorganism of
interest as a means to amplify a signal and thereby detect low levels of a
microorganism (e.g., a
26
CA 03150337 2022-3-7
WO 2021/050939
PCT/US2020/050490
single microorganism) present in a sample. For example, infectious agents
(e.g., bacteriophage)
specifically recognize surface receptors of particular microorganisms and thus
specifically infect
those microorganisms. As such, these infectious agents may be appropriate
binding agents for
targeting a microorganism of interest. As discussed herein, the bacteriophage
may replicate
inside of the bacteria to generate hundreds of progeny phage. Detection of the
product of an
indicator gene inserted into the bacteriophage genome can be used as a measure
of the bacteria in
the sample.
[00951 Some embodiments of the disclosure utilize the
specificity of binding and high-level
genetic expression capacity of recombinant bacteriophage for rapid and
sensitive targeting to
infect and facilitate detection of a bacterium of interest. In some
embodiments, the indicator
bacteriophage is genetically modified to include a reporter gene. In some
embodiments the late
gene region of a bacteriophage is genetically modified to include an indicator
(reporter) gene. In
some embodiments, an indicator gene is positioned downstream of the major
capsid gene. In
other embodiments, an indicator gene is positioned upstream of the major
capsid gene. In some
embodiments, the inserted genetic construct further comprises its own
exogenous, dedicated
promoter to drive expression of the indicator gene. The exogenous promoter is
in addition to any
endogenous promoter in the phage genome. As bacteriophage produce
polyeistronic mRNA
transcripts, only a single promoter is required upstream of the first
genelcistron in the
transcript. Conventional recombinant constructs only use the endogenous
bacteriophage
promoter to drive inserted genes. In contrast, addition of an additional
promoter upstream of the
reporter gene and ribosomal binding site may increase gene expression by
acting as a secondary
initiation site for transcription. The complicated and compact genomes of
viruses often have
overlapping genes in different frames, sometimes in two different directions.
[0096] Some embodiments of methods for preparing a recombinant indicator
bacteriophage
include selecting a wild-type bacteriophage that specifically infects a target
pathogenic
bacterium such as Escherichia con, Cronobacter spp., Salmonella spp., Listerkt
spp., or
Staphylococcus spp.; preparing a homologous recombination plasmidivector that
comprises an
indicator gene; transforming the homologous recombination plasmidivector into
target
pathogenic bacteria; infecting the transformed target pathogenic bacteria with
the selected wild-
27
CA 03150337 2022-3-7
WO 2021/050939
PCT/US2020/050490
type bacteriophage, thereby allowing homologous recombination to occur between
the
plasmid/vector and the bacteriophage genome; and isolating a particular clone
of recombinant
bacteriophage.
[0097] Various methods for designing and preparing a homologous recombination
plasmid
are known. Various methods for transforming bacteria with a plasmid are known,
including
heat-shock, F putts mediated bacterial conjugation, electroporation, and other
methods. Various
methods for isolating a particular clone following homologous recombination
are also known.
Some method embodiments described herein utilize particular strategies_
[0098] Thus, some embodiments of methods for preparing indicator bacteriophage
include the
steps of selecting a wild-type bacteriophage that specifically infects a
target pathogenic
bacterium; determining the natural sequence in the late region of the genome
of the selected
bacteriophage; annotating the genome and identifying the major capsid protein
gene of the
selected bacteriophage; designing a sequence for homologous recombination
adjacent to the
major capsid protein gene, wherein the sequence comprises a codon-optimized
reporter gene;
incorporating the sequence designed for homologous recombination into a
plasmid/vector;
transforming the pIasmidivector into target pathogenic bacteria; selecting for
the transformed
bacteria; infecting the transformed bacteria with the selected wild-type
bacteriophage, thereby
allowing homologous recombination to occur between the plasmid and the
bacteriophage
genome; determining the titer of the resulting recombinant bacteriophage
lysate; and performing
a limiting dilution assay to enrich and isolate the recombinant bacteriophage
Some
embodiments comprise further repeating the limiting dilution and titer steps.
following the first
limiting dilution assay, as needed until the recombinant bacteriophage
represent a detectable
fraction of the mixture. For example, in some embodiments the limiting
dilution and titer steps
can be repeated until at least 1130 of the bacteriophage in the mixture are
recombinant before
isolating a particular clone of recombinant bacteriophage. A ratio of 1:30
recombinant:wild-type
is expected, in some embodiments, to yield an average of 3.2 transducing units
(TU) per 96
plaques (e.g., in a 96-well plate). The initial ratio of recombinant to wild-
type phage may be
determined by performing limiting dilution assays based on the TCID50 (tissue
culture infectious
28
CA 03150337 2022-3-7
WO 2021/050939
PCT/US2020/050490
dose 50%) as previously described in U.S. App. No. 151409,258. By Poisson
distribution, a 1:30
ratio generates a 96% chance of observing at least one TU somewhere in the 96
wells_
[0099] As noted herein, in certain embodiments, it may be
preferred to utilize infectious
agents that have been isolated from the environment for production of the
infectious agents of
the disclosure. In this way, infectious agents that are specific to naturally
derived
microorganisms may be generated.
[01001 There are numerous known methods and commercial products for preparing
plasmids.
For example, PCR, site-directed mutagenesis, restriction digestion, ligation,
cloning, and other
techniques may be used in combination to prepare plasmids. Synthetic plasmids
can also be
ordered commercially (e.g., GeneWiz). Cosmids can also be employed, or the
CR1SPRJCAS9
system could be used to selectively edit a bacteriophage genome. Some
embodiments of
methods of preparing a recombinant indicator bacteriophage include designing a
plasmid that can
readily recombine with the wild-type bacteriophage genome to generate
recombinant genomes.
In designing a plasmid. seine embodiments include addition of a codon-
optimized reporter gene,
such as a luciferase gene. Some embodiments further include addition of
elements into the
upstream untranslated region_ For example, in designing a plasmid to recombine
with the
indicator bacteriophage genome, an upstream untranslated region can be added
between the
sequence encoding the C-terminus of the gp23 1 Major Capsid Protein and the
start codon of the
indicator subunit, such as the HiBiT indicator gene. The untranslated region
can include a
promoter, such as a T7, T4, T4-like, Phage K, MP131, MP115. MP112, IvIP506,
M1387, Rambo,
SAM' promoter. The untranslated region can also include a Ribosomal Entry /
Binding Site
(RBS), also known as a "Shine-Dalgarno Sequence" with bacterial systems.
Either or both of
these elements, or other untranslated elements, can be embedded within a short
upstream
untranslated region made of random sequences comprising about the same GC
content as rest of
the phage genome. The random region should not include an ATG sequence, as
that will act as a
start cod on
[0101] The MCP fragment is a part of a structural gene that encodes a virion
protein_ As
these virion proteins are expressed at a very high level, any genes inserted
into this region can be
expected to have similar expression levels, as long as late gene promoters
and/or other similar
29
CA 03150337 2022-3-7
WO 2021/050939
PCT/US2020/050490
control elements are used. In certain instances, the indicator (e.g., HiBiT)
is fused to the major
capsid protein. In some embodiments, the peptide tag (le,, HiBiT) is fused to
the N-terminus of
the MCP. In other embodiments the peptide tag is fused to the C-terminus of
the MCP.
[0102] In some embodiments, indicator bacteriophages are
genetically engineered to
comprise an indicator gene such as a subunit of a luciferase gene. For
example, an indicator
phase can be specific to a particular bacteria of interest, wherein the senome
comprises the
sequence of the HiBit gene. A recombinant indicator HiBit bacteriophage genome
may further
comprise a consensus promoter of T7, T4, T4-like, Phase K, MP131, MN 15, MPI
12, MP506,
MP87, Rambo, SAPJV I, VII, or another late promoter. In further embodiments,
the promoter is
an exogenous promoter Insertion of an exogenous promoter to drive expression
of an indicator
gene is advantageous in that expression is not limited by the expression of
other phase proteins
(e.g., the major capsid protein).
[0103] Thus, in the embodiment of the recombinant phase generated as a result
of the
recombination, the indicator gene or subunit gene (e.g., HiBiT) is inserted
into the late gene
region, just downstream of the gene encoding the major capsid protein, and
thus creates
recombinant bacteriophage genornes comprising the HiBiT gene_ The construct
may
additionally comprise the consensus promoter of T7, T4, T4-like, Phase K,
MP131, MP115,
MPI12, MP506, MP87, Rambo, SANV1, Vii, or another late promoter or another
suitable
promoter to drive transcription and expression of the luciferase gene. The
construct may also
comprise a composite untransiated region synthesized from several UTRs. This
construct
ensures soluble luciferase is produced such that expression is not limited to
the number of capsid
proteins inherent in the phase display system.
[0104] Recombinant phase generated by homologous recombination of a plasmid
designed
for recombination with the wild-type phase genonie can be isolated from a
mixture comprising a
very small percentage (e.g_, 0.005%) of total phase genomes. Following
isolation, large scale
production may be performed to obtain high titer recombinant indicator phase
stocks appropriate
for use in the detection assay. Furthermore, c-esium chloride isopycnic
density gradient
centrifugation may be used to separate phase particles from contaminating
luciferase protein to
reduce background.
CA 03150337 2022-3-7
WO 2021/050939
PCT/US2020/050490
Methods of Using Infectious Agents for Detecting Bacteria
[0105] As noted herein, in certain embodiments, the disclosure may comprise
methods of
using infectious particles for detecting microorganisms_ The methods of the
disclosure may be
embodied in a variety of ways.
10106] In an embodiment, the invention may comprise a method for detecting a
bacterium of
interest in a sample comprising the steps of. incubating the sample with
bacteriophage that
infects the bacterium of interest, wherein the bacteriophage comprises an
indicator gene or
subunit of an indicator gene such that expression of the indicator gene or
subunit during
bacteriophage replication following infection of the bacterium of interest
results in production of
an indicator protein product; and detecting the indicator protein product,
wherein positive
detection of the indicator protein product indicates that the bacterium of
interest is present in the
sample_ In some embodiments, the indicator protein product is a fusion
protein_ In other
embodiments, the indicator protein product is a soluble, non-fusion protein.
[0107]
In certain embodiments, the assay may be performed
to utilize a general concept that
can he modified to accommodate different sample types or sizes and assay
formats.
Embodiments employing indicator bacteriophage of the disclosure may allow
rapid detection of
specific bacterial strains such as Escherichict coli,Cronobacier s-pp.,
Salmonella spp., Listeria
spp., or Staphylococcus spp, with total assay times under 1.5, 2.0, 2.5, 3.0,
3.5, 4.0; 4_5, 5.0, 5.5,
6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, 10.0, 10.5, 11.0, 11.5, 12, 12.5,
13.0, 13.5, 14.0, 14.5, 15.0,
15.5, 16.0, 16.5, 17.0, 17.5, 18Ø18.5. 19.0, 19.5, 20.0, 21.0, 21.5 22.0,
22.5, 23.0, 23.5, 24.0,
24.5 25.0, 25.5, or 26.0 hours, depending on the sample type, sample size, and
assay format For
example, the amount of time required may be somewhat shorter or longer
depending on the
strain of bacteriophage and the strain of bacteria to be detected in the
assay, type and size of the
sample to be tested, conditions required for viability of the target,
complexity of the
physical/chemical environment, and the concentration of "endogenous" non-
target bacterial
contaminants.
31
CA 03150337 2022-3-7
WO 2021/050939
PCT/US2020/050490
10108] In some embodiments, the phage (e.g., SEA1, TSP1, TSP12, T7, T4, T4-
like, Phage
K, MP131, MP115, MP112, MP506, MP87, Rambo, SAPJV1 phage) may be engineered to
express an indicator gene or subunit during replication of the phage.
Expression of the indicator
gene is driven by a viral capsid promoter (e.g., the bacteriophage T7 or T4
late promoter),
yielding high expression.
101091
Parental phage will express the
indicator protein or subunit (e.g., HiBit). Thus, there
is generally a need to separate out the parental phage from the progeny phage
or remove the
indicator protein or subunit from parental bacteriophage, so that signal in
the assay comes from
replication of progeny phage during infection of the bacterial cells and not
from parental phage.
101101 In some embodiments, there is no background signal or substantially no
background
signal from the parental bacteriophage. In certain instances, the indicator or
subunit (e.g.,
HiBiT) is non-luminescent or substantially non-luminescent.. In further
embodiments, the
indicator or subunit is removed from parental bacteriophage prior to addition
of a substrate, so
the signal detected in the assay must come from replication of progeny phage
during infection of
the bacterial cells. Any method generally known in the art can be used to
remove the indicator
or subunit (e.g., HiBiT) from parental phage_ For example, a protease-
cleavable linker (cleavage
tag) may be cloned into the parental phage. Selection of an appropriate
cleavage tag depends on
the selected bacteriophage. For example, the cleavage tag may be selected from
the group
comprising 3C (PreScission) (LEVLFQ/GP), EKT (enterokinase) (DDDDKO, FKa
(Factor FKa)
(MGR), ITV (tobacco etch virus) (ENLYFQVG), and thrombin (LVPR/GS). The main
cleavage
site for each cleavage tag_ is indicated by the "I". Thus, in some
embodiments, the indicator
phage comprises a protease cut site. For example, the indicator phage may
comprise a fusion of
indicator subunit (peptide)-capsid protein containing a protease cut site. The
protease cut site
may be recombinant, i.e., added or created in the genetic modification
process. In further
embodiments, a protease is added to the parental bacteriophage. In some
embodiments, the
protease is added during phage preparation to remove the indicator subunit
from the parental
bacteriophage, thereby generating a soluble indicator subunit (peptide). In
further embodiments,
the protease is added after the phage have been concentrated. In certain
instances, the protease is
32
CA 03150337 2022-3-7
WO 2021/050939
PCT/US2020/050490
added prior to purification, purified to remove any residual indicator protein
that may be
generated upon production of the infectious agent stock.
101111 The selected protease is specific to the cleavage
tag. 3C, EKT, FXa, TEV, and
thrombin cleavage tags may be cleaved by human rhinovirus (HRV), enterokinase,
Factor FXa,
tobacco etch virus protease, and thrombin, respectively. The specificity of
each cleavage enzyme
varies. For example, HRV is a highly specific protease that cleaves between
the Glu and Gly
residues in the cleavage tag. Enterokinase is an intestinal enzyme normally
involved in the
protease cleavage of Trypsin. It cleaves after the Lysine (K) in is
recognition sequence. Factor
Xa cleaves after the Arg residue but can also cleave less frequently at
secondary basic sites. Its
most common secondary cleavage site is between the Gly and Arg residues in its
own
recognition site, although the frequency of these events is protein specific.
Cleavage by TEV
occurs between the Glu and Gly residues. TEV is often reported to have better
specificity for its
recognition site compared to EKT, Thrombin or Factor Xa. Thrombin cleaves
preferentially
between the Arg and Gly residues. Off target cleavage can occur at non-
specific sites, normally
from contaminating proteases. To ensure maximal protein integrity the enzyme
reagent must be
very pure.
101121 In some embodiments, the sample may be enriched
prior to testing by incubation in
conditions that encourage growth. In such embodiments, the enrichment period
can be 1, 2, 3, 4,
5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16 hours Or longer, depending on the
sample type and size.
101131 In some embodiments, the indicator bacteriophage comprises an indicator
gene, and
infection of a single pathogenic cell (e.g., bacterium) can be detected by an
amplified signal
generated via the expression of the indicator gene. Thus, the method may
comprise detecting an
indicator protein produced during phage replication, wherein detection of the
indicator protein
indicates that the bacterium of interest is present in the sample.
101141 In an embodiment, the disclosure may comprise a method for detecting a
bacterium of
interest in a sample comprising the steps of: incubating the sample with an
indicator
bacteriophage that infects the bacterium of interest, wherein the indicator
bacteriophage
comprises an indicator gene inserted into a late gene region of the
bacteriophage such that
expression of the indicator gene during bacteriophage replication following
infection of host
33
CA 03150337 2022-3-7
WO 2021/050939
PCT/US2020/050490
bacteria results in production of an indicator protein product; incubating the
indicator protein
product with a detection reagent, wherein the detection reagent comprises a
polypeptide
complementary to the indicator protein product, and wherein the indicator
protein product and its
complementary polypeptide for an indicator complex; and detecting the
indicator complex,
wherein positive detection of die indicator complex indicates that the
bacterium of interest is
present in the sample. In some embodiments, the amount of indicator detected
corresponds to
the amount of the bacterium of interest present in the sample.
[0115] As described in more detail herein, the methods and systems of the
disclosure may
utilize a range of concentrations of parental indicator bacteriophage to
infect bacteria present in
the sample. In some embodiments the indicator bacteriophage are added to the
sample at a
concentration sufficient to rapidly find, bind, and infect target bacteria
that are present in very
tow numbers in the sample, such as a single cell. In some embodiments, the
phage concentration
can be sufficient to find, bind, and infect the target bacteria in less than
one hour. In other
embodiments, these events can occur in less than two hours, or less than three
hours, following
addition of indicator phage to the sample. For example, in certain
embodiments, the
bacteriophage concentration for the incubating step is greater than 1 x 105
PFU/mL, greater than
1 x 106 PFLUmL, or greater than 1 x 107 PFUSL.
[0116] In certain embodiments, the infectious agent may be
purified so as to be free of any
residual indicator protein that may be generated upon production of the
infectious agent stock.
Thus, in certain embodiments, the indicator bacteriophage may be purified
using cesium chloride
isopycnic density gradient centrifugation prior to incubation with the sample.
When the
infectious agent is a bacteriophage, this purification may have the added
benefit of removing
bacteriophage that do not have DNA (i.e., empty phage or "ghosts").
[0117] In some embodiments of the methods of the disclosure, the microorganism
may be
detected without any isolation or purification of the microorganisms from a
sample. For
example, in certain embodiments, a sample containing one or a few
microorganisms of interest
may be applied directly to an assay container such as a spin column, a
microtiter well, or a filter
and the assay is conducted in that assay container. Various embodiments of
such assays are
disclosed herein.
34
CA 03150337 2022-3-7
WO 2021/050939
PCT/US2020/050490
10118] Aliquots of a test sample may be distributed
directly into wells of a multi-well plate,
indicator phage may be addexl, and after a period of time sufficient for
infection, a lysis buffer
may be added as well as a substrate for the indicator protein (e.g.,
luciferase substrate for a
luciferase indicator) and assayed for detection of the indicator signal. Some
embodiments of the
method can be performed on filter plates. Some embodiments of the method can
be performed
with or without concentration of the sample before infection with indicator
phage.
[0119] For example, in many embodiments, multi-well plates are used to conduct
the assays.
The choice of plates (or any other container in which detecting may be
performed) may affect the
detecting step. For example, some plates may include a colored or white
background, which
may affect the detection of light emissions. Generally speaking, white plates
have higher
sensitivity but also yield a higher background signal. Other colors of plates
may generate lower
background signal but also have a slightly lower sensitivity. Additionally,
one reason for
background signal is the leakage of light from one well to another, adjacent
well. There are
some plates that have white wells but the rest of the plate is black. This
allows for a high signal
inside the well but prevents well-to-well light leakage and thus may decrease
background. Thus
the choice of plate or other assay vessel may influence the sensitivity and
background signal for
the assay.
[0120] Methods of the disclosure may comprise various
other steps to increase sensitivity.
For example, as discussed in more detail herein, the method may comprise a
step for washing the
captured and infected bacterium, after adding the bacteriophage but before
incubating, to remove
excess parental bacteriophage and/or luciferase or other reporter protein
contaminating the
bacteriophage preparation.
[0121] In some embodiments, detection of the microorganism of interest may be
completed
without the need for culturing the sample as a way to increase the population
of the
microorganisms. For example, in certain embodiments the total time required
for detection is less
than 26.0, 25.0, 24.0, 23.0, 22.0, 21.0,20.0, 19.0, 18.0, 17_0, 16.0 hours,
15.0 hours, 14_0 hours,
110 hours, 12.0 hours, 11.0 hours, 10.0 hours, 9.0 hours, 8,0 hours, 7.0
hours, 61) hours, Si)
hours, 4.0 hours, 3_0 hours, 2.5 hours, 2.0 hours, 1.5 hours, 1.0 hour, 45
minutes, or less than 30
minutes. Minimizing time to result is critical in food and environmental
testing for pathogens.
CA 03150337 2022-3-7
WO 2021/050939
PCT/US2020/050490
[0122] In contrast to assays known in the art, the method
of the disclosure can detect
individual microorganisms. Thus, in certain embodiments, the method may detect
S 10 cells of
the microorganism (i.e., 1, 2, 3, 4, 5, 6, 7, 8, 9 microorganisms) present in
a sample. For
example, in certain embodiments, the indicator bacteriophage is highly
specific for a particular
bacteria of interest. In an embodiment, the recombinant bacteriophage can
distinguish the
bacteria of interest in the presence of other types of bacteria. In certain
embodiments, the
recombinant bacteriophage can be used to detect a single bacterium of the
specific type in the
sample. In certain embodiments, the recombinant bacteriophage detects as few
as 2. 3, 4, 5, 6, 7,
8, 9, 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, or 100 of the specific bacteria
in the sample.
[0123] Thus, aspects of the present disclosure provide methods for
detection of
microorganisms in a test sample via an indicator complex. In some embodiments,
where the
microorganism of interest is a bacterium, one or more subunits of the
indicator complex may be
associated with an infectious agent such as an indicator bacteriophage. The
indicator complex
may react with a substrate to emit a detectable signal or may emit an
intrinsic signal (e.g.,
fluorescent protein). In some embodiments, the detection sensitivity can
reveal the presence of
as few as 50, 20, 10, 9, 8, 7, 6, 5, 4, 3, or 2 cells of the microorganism of
interest in a test sample..
In some embodiments, even a single cell of the microorganism of interest may
yield a detectable
signal. In some embodiments, the bacteriophage is a T4-like or 1v7iI-like
bacteriophage.
[0124] In some embodiments, the indicator protein encoded by the infectious
agent may be
detectable during or after replication of the infectious agent. Many different
types of detectable
biomolecules suitable for use as indicator moieties are known in the art, and
many are
commercially available_ In some embodiments the indicator phage comprises an
indicator gene
encoding an enzyme, which serves as the indicator protein. In other
embodiments, the indicator
phage comprises an indicator gene encoding a subunit of an enzyme, which
serves as the
indicator moiety. In some embodiments, the genome of the indicator phage is
modified to
encode a soluble, non-fusion protein. In other embodiments, the genome of the
indicator phage
is modified to encode a fusion protein. In some embodiments, the indicator
phage encodes a
subunit of a detectable enzyme (Le., indicator protein product). In some
embodiments, the
subunit of the detectable enzyme is incubated in the presence of a
complementary subunit of the
36
CA 03150337 2022-3-7
WO 2021/050939
PCT/US2020/050490
detectable enzyme such that they reconstitute to form a functional enzyme
(i.e., indicator
complex), The indicator complex may emit light and/or may be detectable by a
color change in
an added substrate. Various appropriate enzymes are commercially available,
such as alkaline
phosphatase (AP), horseradish peroxidase (HRP), or luciferase (Luc). In some
embodiments,
these enzymes may serve as the indicator protein. In some embodiments, Firefly
luciferase is
the detectable enzyme. In some embodiments. Oplophorus luciferase is the
detectable enzyme.
In some embodiments, NANOLUC is the detectable enzyme_ In some embodiments, a
HiBiT-
LgBiT complex is the detectable enzyme. In some embodiments, is the detectable
enzyme_
Other engineered luciferases or other enzymes that generate detectable signals
may also be used
with the embodiments described in detail herein.
[0125] In some embodiments, the indicator gene encodes a
subunit of a protein capable of
emitting an intrinsic signal, such as a fluorescent protein (e.g., green
fluorescent protein or
others). The subunit (labeling subunit) of the indicator protein may
reconstitute with a second
subunit of the protein (detection subunit) to form an indicator complex. The
indicator complex
may emit light and/or may be detectable by a color change. In some
embodiments, the indicator
complex is a functional enzyme (e.g., luciferase) that interacts with a
substrate to generate signal.
In some embodiments, the labeling subunit is a subunit of a luciferase gene.
In some
embodiments, the luciferase gene is one of Oplophonts luciferase, Firefly
luciferase, Renilla
luciferase, Gaussia luciferase, Lucia luciferase, or an engineered luciferase
such as
NANOLUC , NANOBIT , Rhic8.6-535, or Orange Nano-lantern.
[0126] Detecting the indicator may include detecting
emissions of light. In some
embodiments, a luminometer may be used to detect the reaction of indicator
(e.g., luciferase)
with a substrate. The detection of RLU can be achieved with a luminometer, or
other machines
or devices may also be used. For example, a spectrophotometer, CCD camera, or
CMOS camera
may detect color changes and other light emissions. Absolute RLU are important
for detection,
but the signal to background ratio also needs to be high (e.g., > 2.0,> 2.5,
or > 3.0) in order for
single cells or low numbers of cells to be detected reliably.
[0127] In some embodiments, the indicator phase is
genetically engineered to contain a
subunit of a gene for an enzyme, such as a luciferase. Thus, the enzyme (e.g.,
luciferase) is only
37
CA 03150337 2022-3-7
WO 2021/050939
PCT/US2020/050490
produced upon infection of bacteria that the phage specifically recognizes and
infects and the
subsequent reconstitution of the labeling subunit expressed on progeny
bacteriophage with the
detection subunit. In certain instances, the indicator moiety is expressed
late in the viral life
cycle. In some embodiments, the indicator is a fusion protein. In other
embodiments, as
described herein, the indicator is a soluble protein (e.g., soluble
luciferase) and is not fused with
a phage structural protein that limits its copy number.
101281 Thus in some embodiments utilizing indicator phase,
the disclosure comprises a
method for detecting a microorganism of interest comprising the steps of
capturing at least one
sample bacterium; incubating the at least one bacterium with a plurality of
indicator phage;
allowing time for infection and replication to generate progeny phage and
express indicator
moiety; reconstituting the indicator moiety with the detection subunit,
thereby forming an
indicator complex; and detecting the progeny phage, or preferably the
indicator complex,
wherein detection of the indicator complex demonstrates that the bacterium is
present in the
sample.
101291 For example, in some embodiments the test sample bacterium may be
captured by
binding to the surface of a plate, or by filtering the sample through a
bacteriological filter (e_g_,
0.45 p.m pore size spin filter or plate fitter). In an embodiment, the
infectious agent (e.g.,
indicator phage) is added in a minimal volume to the captured sample directly
on the filter. In an
embodiment, the microorganism captured on the filter or plate surface is
subsequently washed
one or more times to remove excess unbound infectious agent. In an embodiment,
a medium
(e.g., Luria-Bertani Broth, also called LB herein, Buffered Peptone Water,
also called BPW
herein, or Tryptic Soy Broth or Tryptone Soy Broth, also called TSB herein)
may be added for
further incubation time, to allow replication of bacterial cells and phage and
high-level
expression of the gene encoding the indicator moiety. However, a surprising
aspect of some
embodiments of testing assays is that the incubation step with indicator phage
only needs to be
long enough for a single phage life cycle. The amplification power of using
bacteriophage was
previously thought to require more time, such that the phage would replicate
for several cycles.
A single replication cycle of indicator phage can be sufficient to facilitate
sensitive and rapid
detection according to some embodiments of the present disclosure.
38
CA 03150337 2022-3-7
WO 2021/050939
PCT/US2020/050490
101301 In some embodiments, aliquots of a test sample comprising bacteria may
be applied to
a spin column and after infection with a recombinant bacteriophage and an
optional washing to
remove any excess bacteriophage, the amount of soluble indicator detected will
be proportional
to the amount of bacteriophage that are produced by infected bacteria.
101311 In some embodiments, the progeny phage are lysed prior to incubation
with a
detection reagent comprising the detection subunit. In some embodiments, the
detection reagent
further comprises a substrate. For example, in detection systems utilizing
Nano-Glo HiBiT Lytle
Detection System technology, progeny bacteriophage expressing HiBiT must be
lysed in order
for the complementary polypeptide, LgBiT, to access HiBiT. When HiBiT
encounters LgBiT
they reconstitute to form a functional luciferase enzyme.
[0132] Soluble indicator released into the surrounding
liquid upon lysis of the bacteria may
then he measured and quantified. In an embodiment, the solution is spun
through the filter, and
the filtrate collected for assay in a new receptacle (e.g., in a luminometer)
following addition of a
substrate for the indicator enzyme (e.g.. luciferase substrate).
Alternatively, the indicator signal
may be measured directly on the filter.
[0133] In various embodiments, the purified parental indicator phage does not
comprise the
detectable indicator itself, because the parental phage can be purified before
it is used for
incubation with a test sample. Expression of late (Class III) genes occurs
late in the viral life
cycle. In some embodiments of the present disclosure, parental phage may be
purified to
exclude any existing indicator protein (e.g., hiciferase). In some
embodiments, expression of the
indicator gene during bacteriophage replication following infection of host
bacteria results in a
soluble indicator protein product. Thus, in many embodiments, it is not
necessary to separate
parental from progeny phage prior to the detecting step. In an embodiment, the
microorganism
is a bacterium and the indicator phage is a bacteriophage. In an embodiment,
the indicator
protein is soluble luciferase, which is released upon lysis of the host
microorganism.
[0134] Thus, in an alternate embodiment, the indicator
substrate (e.g., luciferase substrate)
may be incubated with the portion of the sample that remains on a filter or
bound to a plate
surface. Accordingly, in some embodiments the solid support is a 96-well
filter plate (or regular
39
CA 03150337 2022-3-7
WO 2021/050939
PCT/US2020/050490
96-well plate), and the substrate reaction may be detected by placing the
plate directly in the
luminometer,
[0135] For example, in an embodiment, the disclosure may comprise a method for
detecting
Salmonella spp. comprising the steps of: infecting cells captured on a 96-well
filter plate with a
plurality of parental indicator phage capable of expressing luciferase upon
infection; washing
excess phage away; adding LB broth and allowing time for phage to replicate
and lyse the
specific Salmonella spp. target (e.g., 30-120 minutes); and detecting the
indicator luciferase by
adding luciferase substrate and measuring luciferase activity directly in the
96-well plate,
wherein detection of luciferase activity indicates that the Salmonella spp. is
present in the
sample.
[0136] In another embodiment, the disclosure may comprise a method for
detecting
Salmonella spp. comprising the steps of: infecting cells in liquid solution or
suspension in a 96-
well plate with a plurality of parental indicator phage capable of expressing
the indicator gene
upon infection; allowing time for phage to replicate and lyse the specific
Salmonella spp. target
(e.g., 30-120 minutes); and detecting the indicator luciferase by adding
luciferase substrate and
measuring luciferase activity directly in the 96-well plate, wherein detection
of luciferase activity
indicates that the Salmonella spp. is present in the sample. In such an
embodiment no capturing
step is necessary. In some embodiments, the liquid solution or suspension may
be a consumable
test sample, such as a vegetable wash. In some embodiments, the liquid
solution or suspension
may be vegetable wash fortified with concentrated LB Broth, Trypticirryptone
Soy Broth,
Peptone Water or Nutrient Broth. In some embodiments, the liquid solution or
suspension may
be bacteria diluted in LB Broth.
[0137] In some embodiments, the reaction of indicator
protein (e.g., luciferase) with substrate
may continue for 30 minutes or more, and detection at various time points may
be desirable for
optimizing sensitivity. For example, in embodiments using 96-well filter
plates as the solid
support and luciferase as the indicator, huninometer readings may be taken
initially and at 10- or
15-minute intervals until the reaction is completed.
[0138] Surprisingly, high concentrations of phage utilized
for infecting test samples have
successfiffly achieved detection of very low numbers of target microorganism
in a very short
CA 03150337 2022-3-7
WO 2021/050939
PCT/US2020/050490
timeframe. The incubation of phage with a test sample in some embodiments need
only be long
enough for a single phage fife cycle. In some embodiments, the bacteriophage
concentration for
this incubating step is greater than 7 x 106, 8 x 10619x 106, 1.0 x IC, 1.1 x
107, 1.2x 107, 1.3x
107, 1.4 x 107, 15 x 107, 1.6 x 107, 1.7 x 107, 1.8 x 107, 1.9 x 107, 2.0 x
107, 3.0 x 107, 4.0x 107,
5.0 x 107, 6.0 x io, 7.0 x 107, 8.0 x 10, 9.0 x 107, or 1.0 x 108 PFUlmL.
[0139] Success with such high concentrations of phage is
surprising because the large
numbers of phage were previously associated with "lysis from without," which
killed target cells
and thereby prevented generation of useful signal from earlier phage assays.
It is possible that
the clean-up of prepared phage stocks described herein helps to alleviate this
problem (e.g..
clean-up by cesium chloride isopycnic density gradient ultracentrifugation),
because in addition
to removing any contaminating indicator gene associated with the phase, this
clean-up may also
remove ghost particles (particles that have lost DNA). The ghost particles can
lyse bacterial cells
via "lysis from without," killing the cells prematurely and thereby preventing
generation of
indicator signal. Electron microscopy demonstrates that a crude phage lysate
(i.e., before cesium
chloride clean-up) may have greater than 50% ghosts. These ghost particles may
contribute to
premature death of the microorganism through the action of many phage
particles puncturing the
cell membrane. Thus ghost particles may have contributed to previous problems
where high
PFU concentrations were reported to be detrimental. Moreover, a very clean
phage prep allows
the assay to be performed with no wash steps, which makes the assay possible
to perform
without an initial concentration step. Some embodiments do include an initial
concentration
step, and in some embodiments this concentration step allows a shorter
enrichment incubation
time.
101401 Some embodiments of testing methods may further include confirmatory
assays. A
variety of assays are known in the art for confirming an initial result,
usually at a later point in
time. For example, the samples can be cultured (e.g., CHROMAGAR , DYNABEADS
assay,
PCR can be utilized to confirm the presence of the microbial DNA, or other
confirmatory assays
can be used to confirm the initial result.
[0141] In certain embodiments, the methods of the present
disclosure combine the use of a
binding agent (e.g., antibody) to purify and/or concentrate a microorganism of
interest from the
41
CA 03150337 2022-3-7
WO 2021/050939
PCT/US2020/050490
sample in addition to detection with an infectious agent. For example, in
certain embodiments,
the present disclosure comprises a method for detecting a microorganism of
interest in a sample
comprising the steps of: capturing the microorganism from the sample on a
prior support using a
capture antibody specific to the microorganism of interest; incubating the
sample with a
recombinant indicator bacteriophage comprising an indicator gene, wherein the
indicator gene
encodes a first subunit of an indicator protein, thereby producing an amount
of progeny phage
expressing the first subunit: lysing the amount of progeny phage; incubating
the lysed progeny
phage in the presence of a detection reagent, wherein the detection reagent
comprises a second
subunit of an indicator protein, thereby allowing the first subunit and second
subunit to
reconstitute to form an indicator protein complex; and detecting the indicator
protein complex,
wherein positive detection of the indicator protein complex indicates that the
particular bacteria
of interest is present in the sample. In some embodiments synthetic phage are
designed to
optimize desirable traits for use in pathogen detection assays. In some
embodiments
bioinformatics and previous analyses of genetic modifications are employed to
optimize
desirable traits. For example, in some embodiments, the genes encoding phage
tail proteins can
be optimized to recognize and bind to particular species of bacteria. In other
embodiments the
genes encoding phage tail proteins can be optimized to recognize and bind to
an entire genus of
bacteria, or a particular group of species within a genus. In this way, the
phage can be optimized
to detect broader or narrower groups of pathogens. In some embodiments, the
synthetic phage
may be designed to improve expression of the reporter gene. Additionally
and/or alternatively,
in some instances, the synthetic phage may be designed to increase the burst
size of the phage to
improve detection.
101421 In some embodiments, the stability of the phage may be optimized to
improve shelf-
life For example, enzybiotic solubility may be increased in order to increase
subsequent phage
stability_ Additionally and/or alternatively phage thermostability may be
optimized.
Thermostable phage better preserve functional activity during storage thereby
increasing shelf-
life. Thus, in some embodiments, the thermostability andlor pH tolerance may
be optimized.
Systems and Kits of the Disclosure
42
CA 03150337 2022-3-7
WO 2021/050939
PCT/US2020/050490
101431 In some embodiments, the disclosure comprises systems (e.g., automated
systems or
kits) comprising components for performing the methods disclosed herein. In
some
embodiments, indicator phage are comprised in systems or kits according to the
disclosure.
Methods described herein may also utilize such indicator phage systems or
kits. Some
embodiments described herein are particularly suitable for automation andlor
kits, given the
minimal amount of reagents and materials required to perform the method& In
certain
embodiments, each of the components of a kit may comprise a self-contained
unit that is
deliverable from a first site to a second site.
101441 In some embodiments, the disclosure comprises
systems or kits for rapid detection of a
microorganism of interest in a sample. The systems or kits may in certain
embodiments
comprise a component for incubating the sample with an infectious agent
specific for the
microorganism of interest, wherein the infectious agent comprises an indicator
gene and a
component for detecting the indicator protein. In some embodiments of both the
systems and the
kits of the disclosure, the infectious agent is a recombinant bacteriophage
that infects the
bacterium of interest, and the recombinant bacteriophage comprises an
indicator gene encoding a
peptide or polypeptide subunit of an indicator protein. In some embodiments,
the indicator gene
inserted into a late gene region of the bacteriophage is the indicator moiety
such that expression
of the indicator gene during bacteriophage replication following infection of
host bacteria results
in a subunit of an indicator protein product. Thus, some systems further
comprise a detection
reagent, wherein the detection reagent comprises a polypeptide subunit of an
indicator protein,
wherein the polypeptide subunit reconstitutes with the peptide subunit to form
an indicator
protein complex, and a substrate for reacting with an indicator protein
complex to detect the
indicator protein complex. Additionally, some systems further comprise a
component for
capturing the microorganism of interest on a solid support.
[0145] In other embodiments, the disclosure comprises a method, system, or
kit for rapid
detection of a microorganism of interest in a sample, comprising an infectious
agent component
that is specific for the microorganism of interest, wherein the infectious
agent comprises an
indicator moiety, and a component for detecting the indicator protein. In
certain embodiments,
the recombinant bacteriophage is highly specific for a particular bacterium.
43
CA 03150337 2022-3-7
WO 2021/050939
PCT/US2020/050490
[0146] In certain embodiments, the systems and/or kits may fiirther comprise a
component for
washing the captured microorganism sample. Additionally or alternatively, the
systems and/or
kits may further comprise a component for determining amount of the indicator
moiety, wherein
the amount of indicator moiety detected corresponds to the amount of
microorganism in the
sample. For example, in certain embodiments, die system or kit may comprise a
laminometer or
other device for measuring a luciferase enzyme activity.
[0147] In some systems and/or kits, the same component may be used for
multiple steps. In
some systems and/or kits, the steps are automated or controlled by the user
via computer input
and/or wherein a liquid-handling robot performs at least one step.
[0148] Thus in certain embodiments, the disclosure may comprise a system or
kit for rapid
detection of a microorganism of interest in a sample, comprising: a component
for incubating the
sample with an infectious agent specific for the microorganism of interest,
wherein the infectious
agent comprises an indicator moiety: a component for capturing the
microorganism from the
sample on a solid support; a component for washing the captured microorganism
sample to
remove unbound infectious agent; and a component for detecting the indicator
moiety. In some
embodiments, the same component may be used for steps of capturing and/or
incubating and/or
washing (e.g., a filter component). Some embodiments additionally comprise a
component for
determining amount of the microorganism of interest in the sample, wherein the
amount of
indicator moiety detected corresponds to the amount of microorganism in the
sample. Such
systems can include various embodiments and subembodiments analogous to those
described
above for methods of rapid detection of microorganisms. In an embodiment, the
microorganism
is a bacterium and the infectious agent is a bacteriophage. In a computerized
system, the system
may be fully automated, semi-automated, or directed by the user through a
computer (or some
combination thereof).
[0149] In some embodiments, the system may comprise a component for isolating
the
microorganism of interest from the other components in the sample.
[0150] In an embodiment, the disclosure comprises a system
or kit comprising components
for detecting a microorganism of interest comprising: a component for
isolating at least one
microorganism from other components in the sample; a component for infecting
at least one
44
CA 03150337 2022-3-7
WO 2021/050939
PCT/US2020/050490
microorganism with a plurality of a parental infectious agent; a component for
lysing the at least
one infected microorganism to release progeny infectious agents present in the
microorganism;
and a component for detecting the progeny infectious agents, or with greater
sensitivity, a soluble
protein encoded and expressed by the infectious agent, wherein detection of
the infectious agent
or a protein product of the infectious agent, or a subunit thereof, indicates
that the microorganism
is present in the sample. In some embodiments, the system or kit may further
include a
component for reconstituting the subunit of the protein product of the
infectious agent to form a
detectable indicator protein complex The infectious agent may comprise
bacteriophage carrying
the HiBiT indicator gene.
101511 In other embodiments, the disclosure may comprise a kit for rapid
detection of a
microorganism of interest in a sample, the system comprising: a component for
incubating the
sample with an infectious agent specific for the microorganism of interest,
wherein the infectious
agent comprises a subunit of an indicator protein; a component for capturing
the microorganism
from the sample on a solid support; a component for washing the captured
microorganism
sample to remove unbound infectious agent; and a component for detecting the
indicator protein
(Le., a detection reagent). In some embodiments, the detection reagent
comprises a polypeptide
subunit of an indicator protein, wherein the polypeptide subunit reconstitutes
with the peptide
subunit to form an indicator protein complex, and a substrate for reacting
with an indicator
protein complex to detect the indicator protein complex. The same component
may be used for
steps of capturing and/or incubating and/or washing. Some embodiments
additionally comprise
a component for determining amount of the microorganism of interest in the
sample, wherein the
amount of the indicator protein complex detected corresponds to the amount of
microorganism in
the sample. Such kits can include various embodiments and subembodiments
analogous to those
described above for methods of rapid detection of microorganisms. In an
embodiment, the
microorganism is a bacterium and the infectious agent is a bacteriophage.
101521 In some embodiments, a kit may comprise a component for capturing the
microorganism of interest.
101531 In some embodiments, a kit may comprise a component for isolating the
microorganism of interest from the other components in the sample.
CA 03150337 2022-3-7
WO 2021/050939
PCI1LTS2020/050490
101541 These systems and kits of the disclosure include various components. As
used herein,
the term "component" is broadly defined and includes any suitable apparatus or
collections of
apparatuses suitable for carrying out the recited method. The components need
not be integrally
connected or situated with respect to each other in any particular way. The
disclosure includes
any suitable arrangements of the components with respect to each other. For
example, the
components need not be in the same room_ But in some embodiments, the
components are
connected to each other in an integral unit. In some embodiments, the same
components may
perform multiple fimctions.
Computer Systems and Computer Readable Media
101551 The system, as described in the present technique or any of its
components, may be
embodied in the form of a computer system. Typical examples of a computer
system include a
general-purpose computer, a programmed microprocessor, a microcontroller, a
peripheral
integrated circuit element, and other devices or arrangements of devices that
are capable of
implementing the steps that constitute the method of the present technique.
101561 A computer system may comprise a computer, an input device, a display
unit, and/or
the Internet The computer may further comprise a microprocessor. The
microprocessor may be
connected to a communication bus. The computer may also include a memory. The
memory
may include random access memory (RAM) and read only memory (ROM). The
computer
system may further comprise a storage device. The storage device can be a hard
disk drive or a
removable storage drive such as a floppy disk drive, optical disk drive, etc.
The storage device
can also be other similar means for loading computer programs or other
instructions into the
computer system_ The computer system may also include a communication unit.
The
communication unit allows the computer to connect to other databases and the
Internet through
an 1/0 interface. The communication unit allows the transfer to, as well as
reception of data
from, other databases. The communication unit may include a modem, an Ethernet
card, or any
similar device which enables the computer system to connect to databases and
networks such as
LAN, MAN, WAN and the Internet_ The computer system thus may facilitate inputs
from a user
through input device, accessible to the system through I/O interface.
46
CA 03150337 2022-3-7
WO 2021/050939
PCT/US2020/050490
[0157] A computing device typically will include an operating system that
provides
executable program instructions for the general administration and operation
of that computing
device, and typically will include a computer-readable storage medium (e.g., a
hard disk, random
access memory, read only memory, etc.) storing instructions that, when
executed by a processor
of the server, allow the computing device to perform its intended functions.
Suitable
implementations for the operating system and general functionality of the
computing device are
known or commercially available, and are readily implemented by persons having
ordinary skill
in the art, particularly in light of the disclosure herein.
101581 The computer system executes a set of instructions that are stored in
one or more
storage elements, in order to process input data. The storage elements may
also hold data or
other information as desired. The storage element may be in the form of an
information source
or a physical memory element present in the processing machine.
[0159] The environment can include a variety of data stores and other memory
and storage
media as discussed above.. These can reside in a variety of locations, such as
on a storage
medium local to (and/or resident in) one or more of the computers or remote
from any or all of
the computers across the network_ In a particular set of embodiments, the
information may
reside in a storage-area network ("SAN") familiar to those skilled in the art.
Similarly, any
necessary files for performing the functions attributed to the computers,
servers, or other network
devices may be stored locally and/or remotely, as appropriate. Where a system
includes
computing devices, each such device can include hardware elements that may be
electrically
coupled via a bus, the elements including, for example, at least one central
processing unit
(CPU), at least one input device (e.g., a mouse, keyboard, controller, touch
screen, or keypad),
and at least one output device (e.g., a display device, printer, or speaker).
Such a system may
also include one or more storage devices, such as disk drives, optical storage
devices, and solid-
state storage devices such as random access memory ("RAM") or read-only memory
("ROM''),
as well as removable media devices, memory cards, flash cards, etc_
[0160] Such devices also can include a computer-readable
storage media reader, a
communications device (e.g., a modem, a network card (wireless or wired), an
infrared
communication device, etc.), and working memory as described above. The
computer-readable
47
CA 03150337 2022-3-7
WO 2021/050939
PCT/US2020/050490
storage media reader can be connected with, or configured to receive, a
computer-readable
storage medium, representing remote, local, fixed, and/or removable storage
devices as well as
storage media for temporarily and/or more permanently containing, storing,
transmitting, and
retrieving computer-readable information. The system and various devices also
typically will
include a number of software applications, modules, services, or other
elements located within at
least one working memory device, including an operating system and application
programs, such
as a client application or Web browser. It should be appreciated that
alternate embodiments may
have numerous variations from that described above. For example, customized
hardware might
also be used and/or particular elements might be implemented in hardware,
software (including
portable software, such as applets), or both_ Further, connection to other
computing devices such
as network inputloutput devices may be employed_
[0161] Non-transient storage media and computer readable media for containing
code, or
portions of code, can include any appropriate media known or used in the art,
including storage
media and communication media, such as but not limited to volatile and non-
volatile, removable
and non-removable media implemented in any method or technology for storage
and/or
transmission of information such as computer readable instructions, data
structures, program
modules, or other data, including RAM, ROM, EEPROM, flash memory or other
memory
technology, CD-ROM, digital versatile disk (DVD) or other optical storage,
magnetic cassettes,
magnetic tape, magnetic disk storage or other magnetic storage devices, or any
other medium
which can be used to store the desired information and which can be accessed
by the a system
device. Based on the disclosure and teachings provided herein, a person of
ordinary skill in the
art will appreciate other ways and/or methods to implement the various
embodiments.
101621 A computer-readable medium may comprise, but is not limited to, an
electronic,
optical, magnetic, or other storage device capable of providing a processor
with computer-
readable instructions. Other examples include, but are not limited to, a
floppy disk, CD-ROM,
DVD, magnetic disk, memory chip, ROM, RAM, SRAM, DRAM, content-addressable
memory
("CAM"), DDR, flash memory such as NAND flash or NOR flash, an ASIC, a
configured
processor, optical storage, magnetic tape or other magnetic storage, or any
other medium from
which a computer processor can read instructions. In one embodiment, the
computing device
48
CA 03150337 2022-3-7
WO 2021/050939
PCT/US2020/050490
may comprise a single type of computer-readable medium such as random access
memory
(RAM). In other embodiments, the computing device may comprise two or more
types of
computer-readable medium such as random access memory (RAM), a disk drive, and
cache. The
computing device may be in communication with one or more external computer-
readable
mediums such as an external hard disk drive or an external DVD or Blu-Ray
drive.
[0163] As discussed above, the embodiment comprises a processor which is
configured to
execute computer-executable program instructions and/or to access information
stored in
memory. The instructions may comprise processor-specific instructions
generated by a compiler
and/or an interpreter from code written in any suitable computer-programming
language
including, for example, C, C++, C4, Visual Basic, Java, Python, Pen,
JavaScript, and
ActionScript (Adobe Systems, Mountain View, Calif.). In an embodiment, the
computing device
comprises a single processor. In other embodiments, the device comprises two
or more
processors. Such processors may comprise a microprocessor, a digital signal
processor (DSP), an
application-specific integrated circuit (ASIC), field programmable gate arrays
(FPGAs), and
state machines. Such processors may further comprise programmable electronic
devices such as
PLCs, programmable interrupt controllers (PICs), programmable logic devices
(PLDs),
programmable read-only memories (PROMO, electronically programmable read-only
memories
(EPROMs or EEPROMs), or other similar devices.
[0164] The computing device comprises a network interface. In some
embodiments, the
network interface is configured for communicating via wired or wireless
communication links.
For example, the network interface may allow for communication over networks
via Ethernet,
IEEE 802_11 (Wi-Fi), 802.16 (Wi-Max), Bluetooth, infrared, etc. As another
example, network
interface may allow for communication over networks such as CDMA, GSM, UNITS,
or other
cellular communication networks. In some embodiments, the network interface
may allow for
point-to-point connections with another device, such as via the Universal
Serial Bus (USB), 1394
FireWire, serial or parallel connections, or similar interfaces. Some
embodiments of suitable
computing devices may comprise two or more network interfaces for
communication over one or
more networks. In some embodiments, the computing device may include a data
store in addition
to or in place of a network interface.
49
CA 03150337 2022-3-7
WO 2021/050939
PCT/US2020/050490
101651 Some embodiments of suitable computing devices may comprise or be in
communication with a number of external or internal devices such as a mouse, a
CD-ROM,
DV!), a keyboard, a display, audio speakers, one or more microphones, or any
other input or
output devices. For example, the computing device may be in communication with
various user
interface devices and a display. The display may use any suitable technology
including, but not
limited to, LCD, LED, CRT, and the like.
[0166] The set of instructions for execution by the computer system may
include various
commands that instruct the processing machine to perform specific tasks such
as the steps that
constitute the method of the present technique. The set of instructions may be
in the form of a
software program. Further, the software may be in the form of a collection of
separate programs,
a program module with a larger program or a portion of a program module, as in
the present
technique. The software may also include modular programming in the form of
object-oriented
programming. The processing of input data by the processing machine may be in
response to
user commands, results of previous processing., or a request made by another
processing
machine.
101671 While the present disclosure has been disclosed
with references to certain
embodiments, numerous modifications, alterations and changes to the described
embodiments
are possible without departing from the scope and spirit of the present
disclosure, as defined in
the appended claims. Accordingly, it is intended that the present disclosure
not be limited to the
described embodiments, but that it have the MI scope defined by the language
of the following
claims, and equivalents thereof.
EXAMPLES
[0168] The following example describe methods Results depicted in the
following examples
demonstrate detection of a low number of cells, even a single bacterium, in a
shortened time to
results.
Example 1. Soluble TSPI2.Hibit Expression in Salmonella
CA 03150337 2022-3-7
WO 2021/050939
PCT/US2020/050490
101691 A soluble HiBiT TSP12 construct was cloned into pUC57,Arnp plasrnid
giving
TSP12,HR.HiBiT The plasmid was transformed into Salmonella bongori ATCC 43975
and
transformants were selected on LB carbenicillin selective agar. Well isolated
colonies were
selected and inoculated into selective broth and incubated for 2 hours.
Following incubation, 5
1.11, of culture was assayed to determine HiBiT expression using the HiBiT
Lytic Assay Kit
according to the manufacturer's instruction& The detected signal ranged from
11,000-100,000
RLUs/5 uL of culture (Table 1). The plasmid contained all necessary elements
(promoter/RBS
and coding sequence) for soluble HiBiT expression in S. bongori 43975.
Table 1. HUNT signal of S. bongori transformants.
A 107079 11092 X
848 46074 X
98707 31093 X
13 99328 12559 X
70491 15515 X
X X X
X X X
X X X
A 1 6
2 7
3 8
4 9
6 10
TSP12. MINT
101701 The g bongori transfonnant with the highest HiBit signal was then
infected with wild
type TSP12 at a multiplicity of infection (MOD of OA. The phage lysate was
clarified, filtered,
and buffered exchanged. Serial dilutions of phage and phage with host cells
was performed.
Serial dilutions were then analyzed using TU50 assay and PFU titers were
determined (Table 2).
Table 2. Soluble TSP12.HiBit Homologous Recombination Screen
51
CA 03150337 2022-3-7
WO 2021/050939
PCT/US2020/050490
Salmonella bonaori 43975
Phage No.
Score
Dilution cells 50 ul_ cells
1E-08 566 935 1059 746 845 901
0.0
1E-07 556 775 740 664 696 716
0.0
1E-06 602 810 740 736 711 779
0.0
1E-05 628 1779870 2763 1599 1417
1960 0.8
1E-04 563 2163 3303 2450 2716 2533
1.0
1E-03 645 9259 2291 2590 2634 1857
1.0
1E-02 587 2118 2387 2750 2228 2384
1.0
1E-01 522 1689 1605 1816 1718 1725
1.0
4.8 Sum
2.00E+04 TI-166(100uL)
2.00E+05 TU5ohnl_
3.83E+03 Ratio
Example 2. TSP12.MCP-PS-HiBit Expression in Salmonella
101711 A TSP12 major capsid protein (MCP) HiBiT fusion construct was cloned
into
pliC57Amp plasmid. Cloning and sequence verification were performed using.
GeneWiz. The
plasmid was reconstituted and lyophilized. Reconstituted, lyophilized plasmid
was then
transformed into Salmonella bongori ATCC 43975. Transformants were cultured
and selected on
LB carbenicillin selective agar. Isolated colonies were selected and
inoculated into selective
broth and incubated for 2 hours at 37 C. Following incubation, 5 uL of culture
was assayed to
determine HiBiT expression using the HiBiT Lytic Assay Kit according to the
manufacturer's
instructions. The detected HiBiT signal from transformants was approximately
800 RLUs/5 tiL
of culture (Table 3). The plasrnid did not contain all necessary elements for
efficient MCP-
HiBiT expression in S. bongori ATCC 43975. In order for frill expression of
the HiBit fusion
protein to occur, the plasmid must be recombined with TSP12 phage.
Table 3. HiBiT signal of S. &Ingrid transformants.
52
CA 03150337 2022-3-7
WO 2021/050939
PCT/US2020/050490
AX 891 869
B X 90298 869
C X 811 818
DX 801 824
EX 823 864
F X X X
G XX X
HXX X
A 1 6
2 7
3 8
4 9
S 10
F TSP12. MCP-
PS-111131T
101721 The S. bortgori tranformant with the highest HiBit signal was then
infected with wild
type TSP12 at a multiplicity of infection (M01) of 0.1. The phage Iysate was
clarified, filtered,
and buffered exchanged. Serial dilutions of phage and phage with hoist cells
was performed.
Serial dilutions were then analyzed using TU50 assay and PFU titers were
determined (Table 4).
The recombinant phage was detected at 20-80 time the background signal (no
cell control). The
signal was dose dependent and increased with an increase in the number of
phage.
Table 4. TSP12.MCP-PS-HiBit Homologous Recombination Screen
S. bortgoll 43975
Phage
Score
Dilution II cells SO ut_ cells
1E-08 591 787 912 804 633898
1072 0.2
1E-07 574 789 961 956 701
716 0.0
1E-06 604 856 1012 740 656 699 0.0
1E-05 536 3175 957 981 1309 1121
0.2
1E-04 1383 101723 1995 780611
4045 224270 0.6
1E-03 1216 94634 103974 120423 146861 216645
1.0
1E-02 7754 542450 525599 470042 532701
542164 1.0
53
CA 03150337 2022-3-7
WO 2021/050939
PCT/US2020/050490
1E-01 1058201 2454365 23601961 25837831 21806771 2157157
1.0
4.8
Sum
2.00E+04 TU50{100uL)
2.00E-H36 TU5o/mL
3.83E+03
Ratio
Example 3. Homologous Recombination Constructs
[0173] The homologous recombination products are depicted in FIG. At Parent
Phage
indicates the wild type input phage used for recombination. Fusion Protein
identifies the protein
of interest (POI) used for a fusion partner to HiBiT. HR Donor Plasmid
provides the name of the
plasmid transformed into the HR host Vector Backbone provides the name of the
vector used to
clone the HR region (GENEW1Z provided vector). GENEIATIZ clone ID is the
unique identifier
used by GENEWIZ to track the clone are report the QC data. Cleavage Site
indicates which
protease cleavage site was used to connect HiBiT and fusion partner. HR
Host/Stain indicates the
species and strain used in the recombination and isolation infections. The
Phage Lot indicates if
the phage was fully isolated it would be stored (NA) or a large scale prep was
made (Maze Lot
#). An incomplete indicated that the a) recombinant was not stable or b)
unable to be fully
isolated or c) recombination was not attempted.
Example 4. HiBiT Assay Optimization
[0174] Samples were added to the microliter assay well.
Each microliter assay well
containing a sample received the components listed in Table 5 according to the
HiBiT lytic Kit
manufacturer's instructions. The reaction was mixed by nutator for 10 minutes
prior to reading
on the luminometer. Initial experiments of our transformed HR hosts and FIR
infection lysate
revealed a relatively high (-500 RLLI) background signal in media alone.
Table 5. HiBiT Assay Components
Component Lot#
Vol (A)
HiBiT Lytle Assay Suffer 0000346748
50
LgBT: Large BiT subunit 0000363377
0.5
HB Sub: HiBiT NanoGlo
Substrate 0000364833
1
54
CA 03150337 2022- 3- 7
WO 2021/050939
PCT/US2020/050490
Subsequent experiments determined that the elevated background could be
attributed to samples
containing media. Elevated background levels were not detected in assays using
S-M Buffer,
water, or phage in S-M buffer. In an effort to identify the source of the high
background, several
medias were 2-fold serially-diluted in sterile d-water and 100uL of each
assayed as above and
reported in Table 6.
Table 6. Media Background Signals (RLU)
1.=.1
$ 14/
j&Z 7 SteS.
-ter
t
I 14,
toi 1-11
gt ;a aq Q:
at)
k 1.4
ra DC 792 2505 373 446 1348
0.5X 625 2760 330 367 826
9 25X 456 2626
248 276 475
oak =
0.125X 331 2832 260 280 438
C.) 0 28 24 25 20 22
Additionally, several media components were dissolved at twice (2X) the
recommended
concentration in sterile water, serially diluted 2-fold and subjected to the
HiBiT Assay as
described above (Table 7).
Table 7. 2X Media Background Signals (RLU)
= tip
icr a e
co 2
to EL 0)4.
a t, to
co
z
z 2X 566 3288 2042 971 1301
5362
IX 411 3474 2136 907 1188 6104
14 0.5X 274 2578 1648 726 862 5703
at 0.25X 234 2284 1750 968 801 6151
ta 0 18 23 27 25 33 30
[0175] The results indicated that all media tested had high background and
both BHI and
Tryptone (Sigma) had a very high background (2000-6000 RLUs). The signal
appears saturating
even when the media/ component was diluted 8-fold. An experiment was performed
to discern
which component of the Lytic kit assay in conjunction with the BHI is the
cause of the very high
CA 03150337 2022-3-7
WO 2021/050939
PCT/US2020/050490
RLUs in the absence of HiBiT. Table 8 shows the LgBiT component is interacting
with the BIB
to give the high RLU background in the presence of furimazine substrate. Also
noted here is the
true background of LgBiT and furimazine in buffer alone, which was also high
at 110-180
RLUs.
Table 8. Media Component Background Signal (RL1LT)
HiBit Buffer NanoG10 Buffer
coBUI
6 11
Bin+ LgBT
4 21
0111+ LOST + HB sub
13778 8860
0 BM-, LOU- + NG sub
9941 12143
BM+ HB Sub
27 24
0 BM! + NG Sub
31 23
LgBT + HB sub
180 113
[0176] In order to reduce the high background associated with just LgBiT,
media, and
substrate, the concentration of LgBiT was lowered 5-10 fold (Table 9).
[0177] Table 9 shows an approximate 6-fold drop in background signal when
LgBiT was
reduced to 0.05 AL/reaction versus the manufacturer recommended 0.5
JAL/reaction. For all
subsequent HiBiT assays, the LgBiT component was reduced to at /east 0.1
AL/reaction to mitigate
media-associated background RLUs.
Table 9. LgBiT and Media Background Signal
RW
Bill
403
LB
62
TSB
132
TB
65
TMS
15
PBST 18
dH20
11
Example 5. Recombinant phage generation
101781 Recombinant phages expressing either soluble HiBiT or a HiBiT tag fused
to a
structural protein were created by standard infection of host bacteria
containing the homologous
56
CA 03150337 2022-3-7
WO 2021/050939
PCT/US2020/050490
recombination donor plasmid. The homologous recombination (HR) plasmid was
transformed
into the preferred host bacteria by electroporation. Transformants containing
the plasmid were
selected by growth on antibiotic selective plates. The host was grown under
selective pressure to
early-mid log phase and HiBiT activity was measured in the culture.
[0179] Bacterial cells surviving selection and showing HiBiT activity were
then uses as the
host for the HR infection. Log cells were diluted to approximately 1.0E +07
cells/ mL, in media
with antibiotic. Native/wild-type phage were added at a MOI of about 0.05-1.0
and the infection
was incubated for 3-5 hours at a preferred temperature with shaking. Following
incubation, any
remaining bacterial host cells and cell debris were pelleted by centrifugation
at 5000 x g for 5
minutes. The lysate was collected and filtered through a 0.45 micron filter to
eliminate any
remaining host cells.
[0180] Phage lysates were then prepared for an endpoint dilution and plaque
assays to
determine the estimate recombinant/plaque titers. The phage lysate was buffer
exchanges to
remove all unincorporated/host-derived HiBiT by passing the lysate through a
100,000 Dalton
molecular weight cut off spin filter with additional 4 volumes of wash buffer.
Resulting phage
were suspended in 0_5 mL buffer/media and eight 10-fold dilutions were
performed in media_
[0181] Phage titers were then determined by tittering the HR lysate for HiBiT
recombinants
using a TUso Assay (Transducing Units 50%). Wells showing no HiBiT activity
above the
background (phage and media alone) were scored as negative and wells with 3X
background RLUs
were scored as positive. Calculation of TUso titer was based on Reed-Muench
method. The same
serial dilutions were tittered by plaque assay. The TUso titer was compared to
the plaque assay titer
to determine the recombinant/total phase titer ratio.
[0182] If the recombinant/total phage titer ratio was less
than 1/30, limiting dilution
enrichment was performed until the ratio was at or above 1/30. Limiting
dilution enrichment was
performed by dilution of the lysate to include 1-10 Transducing Units in 5 naL
media. Native
host bacteria was then added to the diluted phage at a low MOT and distributed
amongst wells of
a 96-well culture plate. Phage infection was incubated 3-16 hours at 25-37 C_
10% of each well
was subject to HiBiT Assay and top positive wells underwent the phage titer
assays described
57
CA 03150337 2022-3-7
WO 2021/050939
PCT/US2020/050490
above. Sequential limiting dilution enrichments were performed until the
recombinant/total
phage titer ratio was less than 1130.
[0183] Plaque isolation of recombinant phage is performed once a favorable
recombinant
/total titer ratio was achieved_ Individual plaques were isolated and screened
for HiBiT activity.
Positive plaques are passaged at least 3 times to purity Fully isolated
recombinants were
produced by large scale infection and purified by cesium or sucrose gradient
centrifugation.
Example 6. Phage Concentration Optimization of TSPLsHiBiT (TSP1 with soluble
unfused
HiBiT monomer)
[0184] Salmonella typhimurium (ATCC 19585) were cultured for 16-18 hours in
TSB at
37 C. Cells were diluted to 10, 20, 50, 100, 1000, 10000, and 100,000 CallmL.
100 pi, of the
diluted cells were pipetted to give 1, 2, 5, 10, 100, 1000, and 10000
CF1J/well in a white 96-well
plate. 10 pi, of TSPLsHiBit phage at 1.2x104 to 108 PFLT/inL was added to each
well (TABLE
10).
Table 10. HiBiT Phage Assay Plate Layout
Phage/mL 104 P/mL 105 P/mL
105 P/mL 107 P/mL 104 Pima_
A 0 0
0 0 0
1 1
1 1 1
2 2
2 2 2
5 5
5 5 5
10 10
10 10 10
100 100
100 100 100
woo loon
loop woo woo
H 10000 10000 10000 10000
10000
The plate was incubated at 37 C for 2 hours or 3 hours_ 50 pL of master mix
(50 pL Assay
buffer (NanoGlo HiBiT Buffer), 1 pi, NanoGlo HiBit Substrate, and 0.1 tiL
LgRiT protein) was
added to each well, incubated at room temperature on the nutator, and read in
the
GloMax.Thavigator for 1 second. Signal/Background values for the 2 hour
incubation are shown
in FIG. 5. Signal/Background values for the 3 hour incubation are shown in HG.
6. The 3 hour
incubation time had an improved signal/background ratio.
Example 7. Phage Concentration Optimization of TSP12.sHiBit, TSP12 expressing
soluble
HiBiT peptide
58
CA 03150337 2022-3-7
WO 2021/050939
PCT/US2020/050490
101851 Salmonella bongori (ATCC 43975) were cultured for 16-18 hours in TSB at
37 C.
Cells were diluted to 10, 20, 50, 100, 1000, 10000, and 100,000 CFUlml. 100
pit of the diluted
cells were pipetted to give 1, 2, 5, 10, 100, 1000, and 10000 CFUlwell in a
white 96-well plate.
gL of TSPlisHiBit phage at 1.2x104 to 108 PalimL was added to each well (TABLE
10).
5 The plate was incubated at 37 C for 2 hours or 4 hours. 50 iaL of master
mix (50 itL Assay
buffer (NanoGlo HiBiT Buffer), 1 gL NanoGlo HiBit Substrate, and 0.1 gL LgBiT
protein) was
added to each well, incubated at room temperature on the nutator, and read in
the
GloMax,Navigator for 1 second. Signal/Background values for the 4 hour
incubation are shown
in FIG. 7. Signal/Background values for the 3 hour incubation are shown in
FIG. 8. The 4 hour
10 incubation time had an improved signal/background ratio.
Example 8. Phage Concentration Optimization of TSP12.HiBiT-PS-Soc
[0186] Salmonella bongori (ATCC 43975) were cultured for 16-18 hours in TSB at
37 C.
Cells were diluted to 10, 20, 50, 100, 1000, 10000, and 100,000 CFLT/ml. 100
gL of the diluted
cells were pipetted to give 1, 2, 5, 10, 100, 1000, and 10000 CFU/well in a
white 96-well plate.
10 pL of TSP12.HiBit-PS-Soc phage at 1.2x104 to 108 PFU/mL. was added to each
well
(TABLE 10). The plate was incubated at 37 C for 2 hours_ 50 tit of master mix
(50 pi- Assay
buffer (NanoGlo HiBiT Buffer), 1 lit NanoGlo HiBit Substrate, and 0.10_, LgBiT
protein) was
added to each well, incubated at room temperature on the nutator, and read in
the
GloMax/Navigator for 1 second. Signal/Background values for the 2 hour
incubation are shown
in FIG. 9,
Example 9. Level of detection of TSP12.11iBiT-PS-Soc
[0187] Salmonella bongori (ATCC 43975) were cultured for 16-18 hours in TSB at
37 C.
Cells were diluted to 10, 20, 50, 100, 1000, 10000, and 100,000 CF1_1/mI. 100
gL of the diluted
cells were pipetted to give 1, 2, 5, 10, 100, 1000, and 10000 CFU/well in a
white 96-well plate.
10 gL of TSP12-HTS or TSP12-H PS phage at 1.2x107 PFU/mL was added to each
well
(TABLE 10). The plate was incubated at 37 C for 2 hours. 50 gL of master mix
(50 gL Assay
buffer (NanoGlo HiBiT Buffer), 1 gL NanoGlo HiBit Substrate, and 0.1gL LgBiT
protein) was
added to each well, incubated for 10 minutes at room temperature on the
nutator, and read in the
GloMaxThavigator for 1 second_ Signal/Background values are shown in FIG. 10.
59
CA 03150337 2022-3-7
